

# PROGRAM

A scenic photograph of a desert landscape at sunset. In the foreground, there are several saguaro cacti of varying heights. The middle ground is filled with dense desert shrubs and bushes. In the background, a range of rugged mountains is visible under a sky with vibrant orange, yellow, and purple hues from the setting sun.A circular gold-colored logo with a ribbon banner. The text "AANEM" is written in a bold, sans-serif font across the center of the circle. Below the circle, a ribbon banner curves around it, containing the text "70TH ANNIVERSARY" in a smaller, sans-serif font.

AANEM

70TH ANNIVERSARY

# ANNUAL MEETING

Nov. 1-4, 2023 | PHOENIX, ARIZONA

Including sessions by the Myasthenia Gravis Foundation of America, Peripheral Nerve Society, Periodic Paralysis Association, & Dysautonomia International

# Welcome to the 2023 AANEM Annual Meeting

Welcome to the 2023 AANEM Annual Meeting in sunny Phoenix, Arizona. I hope you're as excited as I am for the week ahead, filled with opportunities to expand your medical knowledge, gain insights into the latest developments in our field, and make lasting professional connections.

We have prepared a comprehensive program to keep you engaged and informed throughout the entire meeting. Our three plenary sessions will showcase top-notch speakers exploring disability in NMDs and innovative ways to support our patients. Additionally, you'll have the chance to participate in a diverse selection of sessions and hands-on workshops covering both fundamental and advanced topics.

Beyond the educational sessions, I encourage you to take full advantage of this gathering to reunite with old friends and forge new connections. Join me at the President's Reception on Wednesday evening to officially kick off the conference, at the Abstract Award Reception on Thursday to celebrate our award-winning researchers, at the Happy Hour on Friday to connect with fellow attendees, and at other social events.

Over the years, I've witnessed the profound impact of the AANEM Annual Meeting. It remains, in my opinion, the best NM and EDX-focused gathering out there. Its breadth ensures that everyone finds something of interest, while its intimate size allows for meaningful interactions with speakers and colleagues. The insights you gather here will undoubtedly enrich your practice and research.

To those who are new to the AANEM community or attending this meeting for the first time, I extend a warm and special welcome. Our community of neurologists, physiatrists, technologists, researchers, and collaborators is dedicated to improving the lives of patients with NMDs. If you have any questions or need assistance, the AANEM staff will be available onsite to help you.

I look forward to connecting with you this week. Enjoy the meeting!

Sincerely,

A handwritten signature in black ink, appearing to read "Robert Irwin".

Robert Irwin, MD  
2023 AANEM President





# Plenary Speakers

The 2023 annual meeting plenary sessions will feature a diverse group of experts addressing this year's plenary theme, *Disability and NMDs: The Whole Enchilada*. This timely topic was chosen by AANEM President Robert Irwin, MD, to highlight the importance of supporting patients' quality of life beyond diagnoses and treatments.

## Plenary 1 | Wednesday



### **Sarcopenia: Aging of Skeletal Muscle and Benefits of Exercise** | *Lambert Lecture*

Walter R. Frontera, MD, PhD

- Professor of PM&R, Sports Medicine, and Physiology at the University of Puerto Rico School of Medicine
- Editor-in-Chief of the *American Journal of PM&R*

The aging of the population is one of the most important global challenges of the 21st century. Aging is associated with loss of functioning, and sarcopenia is one of its most important contributors. Dr. Frontera will examine the diagnostic criteria for sarcopenia and discuss the most recent research related to the cellular and physiological changes associated with it. The potential contribution of various types of exercise to the rehabilitation of older adults will also be discussed.

## Plenary 2 | Thursday



### **How the Health Care Team Can Support Patients at Critical Points in Their Disease Course** | *Olney Lecture*

Jodi Wolff, PhD, MSSW

- Vice President of Patient Engagement and Advocacy at Rejuvenate Bio
- Creator and Director of the Jett Foundation's Camp Promise Retreat

Dr. Wolff will discuss how the health care team can support patients at critical junctures in their disease course, including at the time of diagnosis, loss of key functions, increased medical intervention, transition to adulthood, and palliative period. Research related to coping, grief and loss, anxiety and depression, social isolation, and social support and systems will be examined.



### **Adaptive Athletics: Building Confidence in Everything You Do Regardless of Your Circumstances**

Peter Hughes, MEd

- Adaptive Athletics Program Director at the University of Arizona
- Founder of Wheelchair Athletes Worldwide

Mr. Hughes has coached various sports for more than 30 years from the YMCA level to the NCAA and Paralympics and believes people with disabilities should be encouraged to participate in sports. He will discuss how sports can be adapted and beneficial for health, fitness, self-esteem, and confidence regardless of one's situation and explore the added benefits of sports, including increased independence and changing societal views on the disabled population.



**Advocating for Patients Beyond the Clinical Setting: How Providers Can Advance Access and Equality for the NMD Community**

Michael Lewis, MA

- Director of Disability Policy for the Muscular Dystrophy Association

Mr. Lewis has spent more than a decade working in disability rights for various organizations. His passion for disability policy advocacy stems from his experience as an individual with cerebral palsy. Mr. Lewis will review the Muscular Dystrophy Association's advocacy efforts on behalf of people living with NMDs and how providers can join the efforts to advance changes in public policy that will increase access to care, education, employment, transportation, recreation, and more for those with NMDs.



**Disability in Medical Education: Where Is It? | *Reiner Lecture***

Margaret A. Turk, MD

- Vice Chair of the PM&R Department at SUNY Upstate Medical University Norton College of Medicine
- SUNY Distinguished Service Professor of PM&R, Pediatrics, and Public Health and Preventive Medicine

Along with her clinical and leadership contributions to establishing the SUNY Upstate Norton College of Medicine PM&R Department, Dr. Turk has promoted integrating disability education within medical school curricula, locally and nationally. Dr. Turk will examine the state of disability education in medical schools today, promote the need for more active and widespread inclusion of disability in medical education, and provide suggestions for successful curricular development and implementation.



**Making Visible the “Invisible”: Cognitive Disability in DMD | *Surinderjit Singh Young Lecture***

Mathula Thangarajh, MD, PhD

- Assistant Professor of Neurology at Virginia Commonwealth University

Dr. Thangarajh's research work has highlighted the need for holistic assessment of individuals and their families and promoted scientific stewardship, research equity, and advocacy in improving the clinical and research space in DMD. Dr. Thangarajh will summarize efforts to better quantify the unexpected cognitive burden within DMD and other NMDs, explore psychosocial determinants of health, and highlight how community engagement and partnership with advocacy agencies and industry can be harnessed to improve cognitive health in this disease.

# Wednesday | Nov. 1

08:00 am -  
09:30 am

Session

## Advances in Duchenne Treatment and Management

*Grand Sonoran C-D*

Describe the new and emerging drug therapies and treatment approaches in the management of Duchenne muscular dystrophy. Discuss the relative roles of each of these and how they are changing the approach to care for these patients.

**8:00 am:** *Gene Therapy in Duchenne Muscular Dystrophy Across the Lifespan: Milestones and Current Landscape*

Craig M. McDonald, MD

**8:30 am:** *The Future of Gene Therapy in Duchenne: Building on Current Milestones*

Emma Ciafaloni, MD

**1.50**  
CME/CEU

08:00 am -  
09:30 am

Session

## Cardiac and Pulmonary Manifestations of NMDs

*Grand Sonoran J-K*

Confidently diagnose and manage cardiac and pulmonary manifestations that commonly occur in association with NMDs including motor neuron disorders, neuropathies, NMJ disorders, and myopathies; and describe which NMDs commonly feature comorbid cardiac and pulmonary manifestations, and the evidence-based recommendations for diagnostic evaluation and treatment.

**8:00 am:** *Pulmonary Manifestations of NMDs: Work-up and Management*

Michael K. Hehir, MD

**8:45 am:** *Cardiac Manifestations of NMDs*

Nicholas J. Silvestri, MD

**1.50**  
CME/CEU

08:00 am -  
09:30 am

Session

## Effectively Managing Complex Peripheral Nerve Impairments in Collaboration With Surgery

*Grand Sonoran F*

Describe how EMG informs surgical management of neuralgic amyotrophy; contrast application of distal vs. proximal nerve transfers; review the utility of serial EMGs for neuralgic amyotrophy; contrast EMG findings in root avulsions versus brachial plexus injuries; review the benefits and limitations of neuroimaging for detecting root avulsions; and assess how EMG informs surgical management of brachial plexopathy and root avulsions.

**8:00 am:** *Managing Neuralgic Amyotrophy*

Kaye Sedarsky, MD

**8:40 am:** *Managing Root Avulsions and Proximal Plexus Injuries*

Lawrence R. Robinson, MD

**1.50**  
CME/CEU

08:00 am -  
09:30 am

Session

## hATTR With Polyneuropathy: A Can't Miss Diagnosis

*Grand Sonoran E*

Identify red flag symptoms to raise the clinical suspicion for hATTR; describe the stepwise diagnostic approach for hATTR; and list the available treatments for polyneuropathy caused by hATTR.

**8:00 am:** *Treatment of Polyneuropathy Associated With hATTR Amyloidosis*

J. David Avila, MD

**8:25 am:** *Looking for hATTR - Suspicious and Surprises*

Sasha Zivkovic, MD, PhD

**8:50 am:** *Phenotypic Variability of hATTR Amyloidosis*

Diana Mnatsakanova, MD

**1.50**  
CME/CEU

08:00 am -  
12:00 pm

Session

## MGFA Session

The Myasthenia Gravis Foundation of America (MGFA) Medical & Scientific Advisory Council (MSAC) invites clinical and scientific experts to share current and prospective peer-reviewed research focused on myasthenia gravis (MG) and related disorders of the NMJ. The scientific session will include presentations highlighting the latest advancements in our understanding of MG etiology, immunopathology, therapeutic developments, and management. Program and speakers subject to change.

### 8:00 am: Welcome

Samantha Masterson, CEO, MGFA

### 8:05 am: Introduction of Keynote Speaker

Ali A. Habib, MD

### 8:10 am: Unraveling the Puzzle: Game-Changing Biomarker Development in MG

Anna R. Punga, MD, PhD

### 8:55 am: Introduction to Biomarkers and Hot Topics

Ali A. Habib, MD

### 8:57 am: Investigating Immunological Profiles of Thymus in ACHR-MG by SCRNA-SEQ

Yingkai (Kevin) Li, MD

### 9:04 am: A Phase 0 Study Establishing a Robust Cell Assay for the First in Human Trial of CNP-106 for Generalized ACHR+MG

Irawati Kandela, PhD

### 9:11 am: Racial Disparities in Acute Care Utilization Outcomes Among Those With MG

Pushpa Narayanaswami, MD

### 9:18 am: Differences in Clinical Care Between Black and Non-Black Patients With GMG Receiving Eculizumab in the United States

Adrian Kielhorn, MBA

### 9:25 am: Prevalence and Diversity of Myasthenia Gravis in the US: A Cross-Sectional Study of the NIH all of US Research Program Database

Bhaskar Roy, MBBS

### 9:39 am: Break - Visit Posters and Sponsor Tables

### 10:09 am: Introduction to Clinical Trials

Diana Castro, MD

### 10:11 am: Achievement of Minimal Symptom Expression in Acetylcholine-Receptor Antibody-Positive Participants With gMG and Effect on Disease-Specific Measures in Adapt/Adapt+ Studies

James F. Howard, MD

### 10:18 am: MG-ADL and QMG Scores Over Time in Patients with gMG: Post-Hoc Analysis of Mycaring and Open-Label Studies

Vera Bril, MD

### 10:25 am: Zilucoplan in Pediatric Patients with Acetylcholine Receptor Autoantibody-Positive gMG: ZIMYG (MG0014) and ZIMYG+(MG0015) Clinical Study Designs

Sigrid Nilius, PhD

### 10:32 am: Zilucoplan in Pediatric Patients with Acetylcholine Receptor Autoantibody-Positive gMG: ZIMYG (MG0014) and ZIMYG+ (MG0015) Clinical Studies Designs

Miriam L. Freimer, MD

### 10:39 am: Antigen-Specific Immune Therapy (CNP-106) for Treatment of gMG: Rationale and Design of First in Human Randomized Controlled Trial

Irawati Kandela, PhD

### 11:00 am: Introduction to General Practice

Neelam Goyal, MD

### 11:02 am: National Trends in the Utilization of Thymectomy for MG

Jennifer Morganroth, MD, MBA

### 11:09 am: Measuring Adverse Event Burden in MG: Retrospective Validation of the Adverse Event Unit (AEU) With MGTX Trial Data

Michael K. Hehir, MD

### 11:16 am: Management of MG Around the Globe: Consensus Guidelines vs. Realities of Practice

Julia Greenberg, MD

### 11:23 am: Near Fiber EMG: A New Way to Assess Motor Unit Instability and Electrophysiological Temporal Dispersion

Daniel W. Stashuk, PhD

### 11:30 am: MGNATION: A Real World Study Capturing Patient, Healthcare Professional, and Caregiver Perspectives

Pushpa Narayanaswami, MD

### 11:37 am: Results of the MGNET Adapting Disease-Specific Outcome Measures Pilot Trial for Telehealth in MG (Adapt-TELEMG)

Amanda C. Guidon, MD

### 11:55 am: Thank You's

Samantha Masterson, CEO, MGFA

No CME/CEU

# Wednesday | Nov. 1

08:00 am -  
09:30 am

## **The Good, Bad, and Ugly: Planning NCS With Case Studies**

*Grand Sonoran H-I*

Session

Review the instrumentation, pitfalls, and troubleshooting, as well as plan a NCS with case studies.

This is a technologist-focused session. Anyone who has interest in this topic is welcome to attend.

**8:00 am: *Tips, Tricks, and Pitfalls***  
James L. Lewis, R.NCS.T.

**8:25 am: *Planning NCS With Case Studies***  
Daniel B. Simmons, MD

**8:50 am: *Lower Extremity NCS With Case Studies***  
Daniel Pierce, MD

**1.50  
CME/CEU**

10:00 am -  
11:30 am

## **Adult Brachial Plexus**

*Grand Sonoran C-D*

Session

Review the process of evaluating an adult in the multidisciplinary clinic of Michigan for brachial plexus, including the initial assessment with neurology, neurosurgery, physical medicine, and occupational therapy to determine which tests need to be done, e.g. EMG, MRI, and US. Demonstrate how that information is used to determine if an individual needs surgery or not and which surgery is the most helpful in getting the most use out of the arm. We will follow a real case to highlight this process.

This is a technologist-focused session. Anyone who has interest in this topic is welcome to attend.

**10:00 am: *Introduction***  
Teresa Spiegelberg, CNCT, R.NCS.T., R.EEGT, BS

**10:05 am: *Adult Brachial Plexus Injury - Evaluation, Ancillary Studies, and Reconstruction***  
Yamaan Saadeh, MD

**10:25 am: *Pre-Surgical EMG***  
Ann A. Little, MD

**10:40 am: *Adult Brachial Plexus Injury***  
Sarah Johnson, MS, OTRL

**1.50  
CME/CEU**

10:00 am -  
11:30 am

## **Lifestyle Medicine for Common Conditions Encountered in the EDX Laboratory**

*Grand Sonoran E*

Session

Define lifestyle medicine; recognize six key lifestyle interventions to treat lifestyle-related chronic conditions; recommend evidence-based lifestyle medicine interventions for neurological, spine, and MSK conditions commonly encountered in the EDX laboratory; utilize motivational interviewing to assist patients with behavior change; and explore further educational and certification opportunities in lifestyle medicine.

**10:00 am: *Introduction to Lifestyle Medicine***  
Eric J. Morrison, MD

**10:20 am: *Lifestyle Medicine for Spine-Related Pathologies***  
James Eubanks, MD

**10:40 am: *Lifestyle Medicine for Common Conditions Encountered in the EDX Laboratory***  
Evan R. Zeldin, MD

**1.50  
CME/CEU**

10:00 am -  
11:30 am

## **NMDs and Pregnancy**

*Grand Sonoran H-I*

Session

Recognize the challenges and complex decision making in managing NMD patients contemplating pregnancy; identify the incidence of various NMD in pregnancy, impact of NMD on conception, potential complications during labor and delivery, and the need for continued monitoring and a multi-disciplinary approach in management. The session will also focus on pre-pregnancy counseling and the effect of the medications (per FDA categorization) and other treatments on fertility, pregnancy, fetal development, and lactation.

**10:00 am: *Incidence and Management of Various Compression and Nutritional Neuropathies in Pregnancy***  
Iram Zaman, DO

**10:25 am: *Incidence and Management of Inflammatory Neuropathies During Pregnancy***  
Anza B. Memon, MD

**10:45 am: *MG and Pregnancy Considerations***  
Kavita M. Grover, MD

**1.50  
CME/CEU**



# Wednesday | Nov. 1

10:00 am -  
11:30 am

## NMUS in Children

Grand Sonoran J-K

Session

NMUS is a painless technique, which makes it ideal for the assessment of suspected NMDs in children. This session will describe the unique aspects of using NMUS when assessing children, and how US can be combined with EDX in this population.

**10:00 am: Introduction**  
Michael S. Cartwright, MD

**10:10 am: Muscle US in Children**  
Craig M. Zaidman, MD

**10:40 am: Nerve US in Children**  
Michael S. Cartwright, MD

**1.50**  
CME/CEU

10:00 am -  
11:30 am

## US in Performing Arts Medicine

Grand Sonoran F

Session

Discuss common neurogenic and non-neurogenic, MSK mimics of pain in performing artists; recognize common risk factors for injury in the performing artist; and describe NCS and US techniques that may be used to facilitate accurate diagnosis of common presentations in the performing artist.

**10:00 am: Introduction to Performing Arts Medicine**  
Rebecca Dutton, MD

**10:40 am: Nerve Injuries in the Performing Artist**  
Dale Colorado, DO, MPH

**11:10 am: Shoulder/Neck Pathology in Musicians**  
Emily Miller Olson, MD

**1.50**  
CME/CEU

01:30 pm -  
03:00 pm

## Challenging Imaging Cases

Grand Sonoran G

Session

Identify challenging imaging findings encountered on NMUS including anomalies of nerve, muscle, and bone; neoplastic lesions of nerve and nearby structures; and unusual pathologies of nerve and muscle.

Monika Krzesniak-Swinarska, MD

Christopher Geiger, DO

David C. Preston, MD

**1.50**  
CME/CEU

01:30 pm -  
03:00 pm

## Diagnosis and Treatment: Breakthrough Genetic Testing for NMDs

Grand Sonoran F

Session

Recognize how current testing platforms lead to the latest advances in population genomic-driven drug discovery; apply the principles of genetic diagnosis/interpretation in the NM clinic and understand the transition of novel molecular therapeutics into practice; and review ongoing technological advances and clinical trial data utilizing gene therapies for NMD to identify therapeutics that are likely to be in the clinic within the next 5 years.

**1:30 pm: Update on Forthcoming Genetic and Molecular Therapeutics for NMDs**  
Nicolas N. Madigan, MBBCh, PhD

**1:55 pm: Application of Genetic Testing and Novel Molecular Therapeutics in the NM Clinic**  
Jennifer M. Martinez-Thompson, MD

**2:20 pm: Genomics to Gene Therapy in NMDs**  
Zhiyv N. Niu, PhD, FACMG

**1.50**  
CME/CEU

01:30 pm -  
03:00 pm

## MUAP Recruitment Analysis Made Simple

Grand Sonoran C-D

Session

Recognize MUAP firing rates with a high degree of accuracy, determine the recruitment ratios using auditory recognition skills, and determine whether recruitment is normal or abnormal in a variety of examples.

Devon I. Rubin, MD

**1.50**  
CME/CEU



# Wednesday | Nov. 1

01:30 pm -  
03:00 pm

Session

## The Spectrum of NM Complications of SARS-CoV-2 Infection and Vaccination

Grand Sonoran J-K

Describe the mechanisms of SARS-CoV-2 infections and vaccine-induced immunity and autoimmunity with respect to immune-mediated NMDs; recognize the facts from the myths surrounding SARS-CoV-2 vaccine safety issues for NMDs and provide a balanced analysis of vaccine risks and benefits; discuss the current evidence-based medicine recommendations regarding the diagnosis and treatment of NM manifestations of SARS-CoV-2 infection including post-acute sequelae of SARS-CoV-2 infection; and discuss general rehabilitation principles for NM manifestations of SARS-CoV-2 infection, including post-acute sequelae and interventions to avoid intubation and facilitate decannulation of patients who underwent tracheotomies.

**1:30 pm:** *The Spectrum of NM Complications of SARS-CoV-2 Infection and Vaccination: The Known and the Speculative*  
Nizar Souayah, MD

**2:10 pm:** *Management of Respiratory Complications of SARS-CoV-2*  
John R. Bach, MD

**1.50**  
CME/CEU

01:30 pm -  
03:00 pm

Session

## Toxic Myopathies and Neuropathies

Grand Sonoran E

Identify iatrogenic and noniatrogenic causes of muscle and nerve toxicity; articulate the mechanisms underlying muscle and nerve toxicity; diagnose and classify various forms of toxic myopathies and neuropathies based on their clinical presentation, EDX findings, and histopathologic characteristics; and manage toxic myopathies and neuropathies.

**1:30 pm:** *Introduction*  
Mohammad K. Salajegheh, MD

**1:35 pm:** *Toxic Neuropathies*  
Mohammad K. Salajegheh, MD

**2:10 pm:** *Toxic Myopathies*  
Christopher Doughty, MD

**1.50**  
CME/CEU

01:30 pm -  
03:00 pm

Session

## Updates on CMT, GBS, and Diabetic Neuropathy

Grand Sonoran H-I

Review advances in the development of treatments for CMT; discuss the activities and results of research collaborations through the International GBS Outcome Study; and review the clinical picture, diagnosis, and treatment of diabetic radiculoplexus neuropathy.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through joint providership of AANEM and the Peripheral Nerve Society. The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

**1:30 pm:** *Emerging Treatments for Inherited Neuropathies*  
Vera Fridman, MD

**1:55 pm:** *Updates From the International GBS Outcome Study Group*  
Mazen M. Dimachkie, MD

**2:20 pm:** *Diagnosis and Management of Diabetic Radiculoplexus Neuropathies*  
Marcus Vinicius R. Pinto, MD

**1.50**  
CME/CEU

# Wednesday | Nov. 1

04:00 pm -  
05:30 pm

Session

## Plenary 1: Disability and NMDs: The Whole Enchilada

*Grand Sonoran E-G*

The aging of the population is one of the most important global challenges of the 21st century. Aging is associated with loss of functioning and sarcopenia is one of its most important contributors. We will examine the diagnostic criteria for sarcopenia and discuss the most recent research related to the cellular and physiological changes associated with it. The potential contribution of various types of exercise to the rehabilitation of older adults will also be discussed.

Note: AANEM's Annual Business Meeting will be held at the beginning of this session. Fellow, Active, and Research members will have the opportunity to vote and are encouraged to attend.

### 4:00 pm: *Introduction*

Earl J. Craig, MD

### 4:05 pm: *Disability and NMDs*

Robert W. Irwin, MD

### 4:25 pm: *Annual Business Meeting: Election of Officers*

Robert W. Irwin, MD

### 4:35 pm: *Recognize Outgoing Committee Members*

Robert W. Irwin, MD

### 4:40 pm: *Introduction*

Robert W. Irwin, MD

### 4:45 pm: *Sarcopenia: Aging of Skeletal Muscle and Benefits of Exercise*

Walter Frontera, MD

### 5:15 pm: *Awards: Golseth, Best Abstract, Best Abstract Runner-up, Medical Student Research, Residency and Fellowship Members*

Robert W. Irwin, MD

### 5:30 pm: *Closing*

Robert W. Irwin, MD

1.50  
CME/CEU

# Thursday | Nov. 2

## 08:00 am - 09:30 am **Basics of NCS and Needle EMG - Part 1** *Grand Sonoran E*

Session

Articulate the basic concepts underlying nerve conduction and approach to the study; conduct and interpret NCSs in the upper and lower extremities and identify anomalous innervations; utilize specialized studies including RNS, cranial nerve studies, and blink reflex; apply needle EMG for the diagnosis of NMDs; and recognize common pitfalls and explain technical factors and important safety considerations affecting the study.

**8:00 am: Introduction**  
Kelly G. Gwathmey, MD

**8:10 am: Basic NCS and Approach to Study**  
Mohammad K. Salajegheh, MD

**8:50 am: Upper and Lower Extremity NCS**  
Kelly G. Gwathmey, MD

**1.50**  
CME/CEU

## 08:00 am - 09:30 am **Cutting-Edge US and NM Imaging** *Grand Sonoran C-D*

Session

Assess the role of muscle US in diagnosing FSHD and monitoring its progression; review how NMUS is used in the intensive care setting; and discuss the need for improved shear wave imaging of muscle, alongside its development.

**8:00 am: Muscle US as a Biomarker for FSHD**  
Sjan Teeselink, MD

**8:25 am: NMUS in the ICU**  
Aarti Sarwal, MD

**8:50 am: The Path to 3-D Shear Wave Muscle Imaging**  
Lisa D. Hobson-Webb, MD

**1.50**  
CME/CEU

## 08:00 am - 09:30 am **Inflammatory Myopathies** *Grand Sonoran J-K*

Session

Utilize myositis specific autoantibodies and muscle pathology in diagnosis of patients with suspected inflammatory myopathies; diagnose and treat patients with various subtypes of inflammatory myopathies; and recognize the importance of multidisciplinary approaches in the management of patients with inflammatory myopathies.

**8:00 am: Introduction**  
Teerin Liewluck, MD

**8:03 am: Dermatomyositis and Antisynthetase Syndrome in 2023**  
Rohit Aggarwal, MD

**8:23 am: Inclusion Body Myositis in 2023**  
Anthony A. Amato, MD

**8:43 am: Immune Mediated Necrotizing Myopathy in 2023**  
Andrew L. Mammen, MD, PhD

**9:03 am: Immune Checkpoint Inhibitor in Myopathy in 2023**  
Teerin Liewluck, MD

**1.50**  
CME/CEU

## 08:00 am - 09:30 am **MG: How Far Have We Come?** *Grand Sonoran F*

Session

Identify antibodies supportive of the diagnosis of MG; describe the clinical presentation of MG based on Ab status; discuss the utility of other confirmatory tests for MG; review the impact of MG on physical function and well-being; discuss standard MG outcome measures in the clinic; describe the assessment and challenges of managing MG fatigue; discuss established therapies for MG; discuss the effectiveness of thymectomy, rituximab, and methotrexate; review the definition of refractory MG; and describe novel therapies in the clinic and promising therapies in research.

**8:00 am: Introduction**  
Mazen M. Dimachkie, MD

**8:05 am: Autoantibodies and Phenotypes in MG**  
Mamatha Pasnoor, MD

**8:30 am: Measuring Change in MG**  
Srikanth Muppidi, MD

**8:55 am: The Evolving Therapeutics of MG**  
Mazen M. Dimachkie, MD

**1.50**  
CME/CEU



# Thursday | Nov. 2

08:00 am -  
09:30 am

Session

## **MSK US for MSK Conditions Encountered During an NM Evaluation**

*Grand Sonoran G*

Identify common MSK problems that can confound symptoms and NM evaluation with the use of high frequency US; discuss MSK dilemmas facing NM specialists; and describe the techniques for identifying confounding concomitant MSK comorbidities. This will be an interactive session that will include PowerPoint slides, live discussion, and live US demonstrations.

Craig M. Zaidman, MD

Jeffrey A. Strakowski, MD

**1.50**  
CME/CEU

08:00 am -  
09:30 am

Session

## **The Role of Rehabilitation Medicine in NM Care: The Value of Integrating PM&R Into the Care Plan**

*Grand Sonoran H-I*

Describe how the rehabilitation model of care differs from the medical model of care, review the application and value of functional outcomes in care of the NM patient, describe the role of the physiatrist in care of the NM patient, and review the past, present, and future roles of rehabilitation medicine in the care of the NM patient.

*Looking Back to Inform the Future: The History of  
NM PM&R*

Ileana Howard, MD

*Venn We Get Together: Optimizing PM&R Care  
Integration*

Erik R. Ensrud, MD

*Venn We Get Together: Optimizing PM&R Care  
Integration*

Vovanti Jones, MD

*Expanding Horizons: The Role of PM&R in  
Evolving NM Care Models*

Kathryn A. Mosher, MD

*Expanding Horizons: The Role of PM&R in  
Evolving NM Care Models*

Robert Rinaldi, MD

**1.50**  
CME/CEU

10:00 am -  
12:00 pm

Session

## **Plenary 2: Disability and NMDs: The Whole Enchilada**

*Grand Sonoran E-G*

Discuss how the health care team can support patients at critical junctures in their disease course, including at the time of diagnosis, loss of key functions, increased medical intervention, transition to adulthood, and palliative period. Research related to coping, grief and loss, anxiety and depression, social isolation, and social support and systems will be examined.

Discuss experiences as an athlete and coach and how sport can be used and adapted regardless of the situation to benefit individuals' health, fitness, self-esteem, and confidence. A person who has a disability should not be excluded from sport, rather should be encouraged every step of the way as it has added benefits for people with disabilities such as increasing independence and changing societal views on the disabled population.

**10:00 am: Welcome**

Earl J. Craig, MD

**10:05 am: ANF International and IFCN  
Scholarships**

Robert W. Irwin, MD

**10:10 am: President's Research Initiative Award  
Recipients**

Robert W. Irwin, MD

**10:20 am: Introduction**

Earl J. Craig, MD

**10:25 am: How the Health Care Team Can  
Support Patients at Critical Points in Their  
Disease Course**

Jodi Wolff, PhD, MSSW

**10:55 am: Introduction**

Earl J. Craig, MD

**11:00 am: Adaptive Athletics: Building  
Confidence in Everything You Do Regardless of  
Your Circumstances**

Peter Hughes, MEd

**11:30 am: Closing**

Earl J. Craig, MD

**2.00**  
CME/CEU

# Thursday | Nov. 2

## 01:15 pm - 02:45 pm **Basics of NCS and Needle EMG - Part 2** *Grand Sonoran E*

Session

Articulate the basic concepts underlying nerve conduction and approach to the study; conduct and interpret NCSs in the upper and lower extremities and identify anomalous innervations; utilize specialized studies, including RNS, cranial nerve studies, and blink reflex; apply needle EMG for the diagnosis of NMDs; recognize common pitfalls; and explain technical factors and important safety considerations affecting the study.

**1:15 pm: *Specialized Studies and Needle EMG Basics***  
Aaron Izenberg, MD

**2:05 pm: *Study Pitfalls and Troubleshooting***  
Joseph M. Choi, MD

**1.50  
CME/CEU**

## 01:15 pm - 02:45 pm **EDX and US Evaluation of Neuralgic Amyotrophy - Part 1** *Grand Sonoran G*

Session

Identify sonographic landmarks and anatomic appearance of the brachial plexus and nerves often affected by neuralgic amyotrophy, and describe an electrophysiologic approach to assessing neuralgic amyotrophy and other NM conditions within the differential diagnosis.

**1:15 pm: *Live Demonstration of US Scanning of Neuralgic Amyotrophy***  
Jeffrey A. Strakowski, MD

**1:45 pm: *EDX Assessment of Neuralgic Amyotrophy***  
Devon I. Rubin, MD

**1.50  
CME/CEU**

## 01:15 pm - 02:45 pm **EDX NM Challenging Cases - Part 1** *Grand Sonoran F*

Session

Apply and refine the process of diagnostic formulation in NM medicine and clinical EMG and improve patient care by presenting and discussing challenging cases. [This session relies on AANEM members to provide challenging cases.]

**1.50  
CME/CEU**

Bashar Katirji, MD

## 01:15 pm - 02:45 pm **NM Complications of Cancer Care** *Grand Sonoran C-D*

Session

Familiarize participants with the common NM complications of cancer care, including chemotherapy induced peripheral neuropathy and NM immune related adverse events such as MG, myositis, etc. and review diagnosis, prevention, treatment, and use of current guidelines for these disorders. The session will conclude with real world cases to provide examples of how these principles work in practice.

**1:15 pm: *A Practical Guide to Diagnosis, Prevention, and Treatment of Chemotherapy Induced Peripheral Neuropathy***  
Noah A. Kolb, MD

**1:40 pm: *The NM Complications of Cancer Immunotherapy***  
Amanda C. Guidon, MD

**2:05 pm: *Real World Cases of CIPN and irAE-NM: From Diagnosis to Treatment***  
Brendan L. McNeish, MD

**1.50  
CME/CEU**

## 01:15 pm - 02:45 pm **Peripheral Nerve and Muscle Pathology: Practical Considerations** *Grand Sonoran H-I*

Session

Recognize clinical situations to order nerve and muscle biopsies; correlate nerve and muscle pathology with EMG and imaging abnormalities; and review important nerve and muscle biopsy pathology findings for the UCNS board examination.

**1:15 pm: *Peripheral Nerve Pathology - Case-Based Approach***  
Michelle L. Mauermann, MD

**1:45 pm: *Muscle Pathology: Case-Based Discussions***  
Aziz Shaibani, MD

**1.50  
CME/CEU**

# Thursday | Nov. 2

01:15 pm -  
02:45 pm

Session

## **SMA Treatment for Adults: Pearls and Pitfalls**

*Grand Sonoran J-K*

Identify adult SMA patients who are candidates for disease-modifying therapy, choose the best treatment option, and manage the therapy and other aspects of adult SMA care.

### **1:15 pm: Introduction**

Stacy E. Dixon, MD, PhD

### **1:20 pm: Use of Nusinersen in Adult SMA Patients and Unique Administration Options**

Manisha K. Korb, MD

### **1:45 pm: Use of Risdiplam in Adult SMA Patients and Updates on "Real World" Experience**

Chamindra G. Laverty, MD

### **2:10 pm: Management of Adult SMA Patients and Unique Experiences Encountered**

Stacy E. Dixon, MD, PhD

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## **Building a Successful EDX/NMUS Practice: A Case-Based Approach**

*Grand Sonoran C-D*

Discuss the fundamental elements of a successful medical practice which meets the needs of your "customers" (patients and referral sources) across academic and employed practice settings; implement strategies to align your EDX practice with the needs of patients, referring providers, and the changing landscape in terms of patient access to the EHR; and describe situations where NMUS can help in growing an EDX practice.

### **3:45 pm: Introduction**

John W. Norbury, MD

### **3:50 pm: Private Practice**

Collin Grant, MD

### **4:10 pm: Academic PM&R/NMUS**

Haibi Cai, MD

### **4:30 pm: Large Academic Neurology**

Ruple S. Laughlin, MD

### **5:00 pm: Panel Discussion**

Panel

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## **EDX and US Evaluation of Neuralgic Amyotrophy - Part 2**

*Grand Sonoran G*

Recognize the scientific basis for using NMUS characteristics in neuralgic amyotrophy and similar conditions, identify normal and abnormal US findings of the brachial plexus and other nerves frequently affected by neuralgic amyotrophy, and describe effective integration of EDX and US techniques in evaluating neuralgic amyotrophy. The session will utilize case studies.

### **3:45 pm: NMUS Evaluation**

Michael S. Cartwright, MD

### **4:15 pm: Clinical Cases Combining the Use of Both EDX and US for Neuralgic Amyotrophy**

Jeffrey A. Strakowski, MD

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## **EDX NM Challenging Cases - Part 2**

*Grand Sonoran F*

Apply and refine the process of diagnostic formulation in NM medicine and clinical EMG and improve patient care by presenting and discussing challenging cases. [This session relies on AANEM members to provide challenging cases.]

**1.50**  
CME/CEU

Bashar Katirji, MD

03:45 pm -  
05:15 pm

Session

## **Everything You Wanted to Know About Nerves, but Were Afraid to Ask**

*Grand Sonoran J-K*

Review the peripheral nerves and cranial nerves, and review how to assist in performing RNS.

This is a technologist-focused session. Anyone who has interest in this topic is welcome to attend.

### **4:00 pm: Basic Neurophysiology**

Ann A. Little, MD

### **4:30 pm: Cranial Nerves and Repetitive Stimulation**

Clark A. Moser, MD

**1.50**  
CME/CEU



# Thursday | Nov. 2

03:45 pm -  
05:15 pm

## Pediatric EMG Cases

*Grand Sonoran H-I*

Session

Explore the role of EMG in the pediatric population and give different examples of cases in which it contributed substantially to diagnosis and/or management.

**3:45 pm:** *A Case of Mistaken Identity?*

Kathryn A. Mosher, MD

**4:05 pm:** *Pediatric EMG Cases: A Toddler With Deteriorating Gait*

Nancy L. Kuntz, MD

**4:25 pm:** *Neuropathies Status Post Cardiac Surgery*

Jaclyn C. Omura, MD

**4:55 pm:** *Scapular Dysfunction*

Carly J. Rothman, DO

1.50  
CME/CEU

**5:15 pm:** *Pediatric EMG Cases*

Gabrielle Nguyen, MD

03:45 pm -  
05:15 pm

## Selected Topics on MG

*Grand Sonoran E*

Session

Summarize how to discuss with myasthenic patients general care topics such as proper nutrition, exercise, infection control, immunization, and preparation for surgery; recognize medication influence on MG; review how to avoid medication induced exacerbation; and discuss how to diagnose and manage myasthenic crisis.

**3:45 pm:** *General Care of Patients With MG*

Yuebing Li, MD, PhD

**4:14 pm:** *Medication Induced Exacerbation of MG*

Michael K. Hehir, MD

**4:41 pm:** *Myasthenic Crisis - Diagnosis and Management*

Benjamin Claytor, MD

1.50  
CME/CEU

# Friday | Nov. 3

08:00 am - 09:30 am	<b>Myalgia and Muscle Stiffness: Approach and Management - Part 1</b> <i>Grand Sonoran J-K</i>
Session	Classify and identify causes of muscle pain and stiffness, diagnose and manage various forms of myotonic disorders, and differentiate and treat various forms of metabolic myopathies.
1.50 CME/CEU	<p><b>8:00 am: Introduction</b> Mohammad K. Salajegheh, MD</p> <p><b>8:10 am: Myotonic Disorders</b> Mohammad K. Salajegheh, MD</p> <p><b>8:40 am: Metabolic Myopathies</b> Joome Suh, MD</p>
08:00 am - 09:30 am	<b>NM Sports Medicine Cases: Mechanisms of Injury and Management of Athletes</b> <i>Grand Sonoran C-D</i>
Session	Sports injuries primarily involve the MSK systems, however, injuries to the peripheral nerves and CNS are increasingly more common, especially in the era of extreme sports. These sports injuries can lead to catastrophic consequences if unrecognized and untreated. This session will use case-based presentations to highlight key features in EDX and NM management of these sports injuries. We will look at NM and skeletal injuries as they present in the emergency room and outpatient setting. Through a case-based teaching approach, attendees will be able to identify the epidemiology of sports injuries and the injuries that are unique to different sports, and explain the role of imaging, especially US as an emerging tool in evaluation and management.
1.50 CME/CEU	<p><b>8:00 am: NM Sports Medicine Cases: Mechanisms of Injury and Management of Athletes</b> Catherine Alessi, MD</p> <p><b>8:00 am: NM Sports Medicine Cases: Mechanisms of Injury and Management of Athletes</b> Anthony G. Alessi, MD</p> <p><b>8:30 am: Neurologic Evaluation of Cervical Spine Injuries in Sports</b> Stephanie Alessi-LoRosa, MD, MPH</p> <p><b>9:00 am: TOS/Brachial Plexus Injuries in Athletes</b> Vernon Williams, MD</p>

08:00 am - 09:30 am	<b>Pathologies in NMUS: Common and Uncommon Findings</b> <i>Grand Sonoran E</i>
Session	Review a variety of case-based examples of pathologies seen using NMUS. Emphasis will be on practical applications covering mononeuropathies, polyneuropathy, and muscle diseases as well as anatomical variations and other red herrings.
1.50 CME/CEU	<p><b>8:00 am: Mononeuropathies</b> David C. Preston, MD</p> <p><b>8:20 am: Polyneuropathies</b> Monika Krzesniak-Swinarska, MD</p> <p><b>8:40 am: Muscle Diseases</b> Craig M. Zaidman, MD</p> <p><b>9:00 am: Anatomical Variants and Red Herrings</b> Rocio C. Garcia Santibanez, MD</p>
08:00 am - 09:30 am	<b>Update on ALS: Pathophysiology, Diagnostic Tools, and Pharmacological Treatment</b> <i>Grand Sonoran H-I</i>
Session	Recognize various presentations of ALS; screen for other mimicking conditions; optimize EDX tools and learn to use new and emerging diagnostic tools (e.g. neurofilament light chain); explain the current understanding on the mechanisms of ALS and development of therapies (basic science and clinical research update), and prescribe approved disease modifying therapies.
1.50 CME/CEU	<p><b>8:00 am: Introduction</b> Bjorn E. Oskarsson, MD</p> <p><b>8:05 am: Pathophysiology</b> Bjorn E. Oskarsson, MD</p> <p><b>8:30 am: Diagnostic Tools in the Evaluation of ALS</b> Jennifer M. Martinez-Thompson, MD</p> <p><b>9:00 am: Pharmacological Treatments</b> Stephen Johnson, MD</p>
08:00 am - 09:30 am	<b>US Evaluation of Post-Surgical Median Neuropathy in Carpal Tunnel</b> <i>Grand Sonoran G</i>
Session	Develop a systematic US approach to evaluating persistent problems following carpal tunnel surgery.
1.50 CME/CEU	<p>Jeffrey A. Strakowski, MD</p>

10:00 am -  
12:15 pm

Session

## Plenary 3: Disability and NMDs: The Whole Enchilada

Grand Sonoran E-G

Review MDA's advocacy efforts on behalf of people living with NMDs and how providers can join the efforts to advance changes in public policy that will increase access to care, education, employment, transportation, recreation, and more for those with NMDs.

Examine the state of disability education in medical schools today, promote the need for more active and widespread inclusion of disability in medical education, and provide suggestions for successful curricular development and implementation.

Summarize efforts to better quantify the unexpected cognitive burden within DMD and other NMDs, explore psychosocial determinants of health, and highlight how community engagement and partnership with advocacy agencies and industry can be harnessed to improve cognitive health in this disease.

Achievement Awards presentation will take place at the beginning of the Plenary.

**10:00 am:** *Welcome*

Robert W. Irwin, MD

**10:05 am:** *Awards: Lifetime Achievement, Distinguished Physician, Jun Kimura Outstanding Educator, Ernest Johnson Outstanding Educator, Distinguished Researcher, Scientific Impact, Outstanding Service, Honorary Member, and Public Recognition*

Andrea J. Boon, MD

**10:20 am:** *Introduction*

Ileana Howard, MD

**10:25 am:** *Advocating for Patients Beyond the Clinical Setting: How Providers Can Advance Access and Equality for the NMD Community*

Michael Lewis, MA

**10:55 am:** *Introduction*

Ileana Howard, MD

**11:00 am:** *Disability in Medical Education: Where is it?*

Margaret A. Turk, MD

**11:30 am:** *Introduction*

Ileana Howard, MD

**11:35 am:** *Making Visible the "Invisible": Cognitive Disability in DMD*

Mathula Thangarajh, MD, PhD

**12:00 pm:** *Annual Meeting 2024*

Dianna Quan, MD

2.00

CME/CEU

01:15 pm -  
02:45 pm

Session

## EDX Education for Trainees: Challenges, Strategies, and Novel Approaches for Training

Grand Sonoran G

Recognize the complexities of teaching EDX skills, evaluate potential innovative methods to teach EDX procedure and interpretation skills, and contrast different methods of assessment in trainees learning about EDX skills. Attendees will be able to apply strategies to current educational problems in their own institutions.

Sandra L. Hearn, MD

Devon I. Rubin, MD

Zachary N. London, MD

Leslie Rydberg, MD

1.50  
CME/CEU

01:15 pm -  
02:45 pm

Session

## Hot Topics in NM Literature - Part 1

Grand Sonoran E

Appraise several impactful findings in NM literature over the past year; recognize the clinical value of these studies and their impact to NM patients (EDX and sonographic methods, hereditary and acquired myopathy evaluation, peripheral neuropathy testing and treatment, motor neuron disease understanding, and NMJ disorder advancements); describe hot topics and groundbreaking work in these areas of NM medicine; and integrate emerging knowledge into clinical practice.

**1:15 pm:** *Introduction*

Ruple S. Laughlin, MD

**1:20 pm:** *Hot Topics in Clinical Neurophysiology: EDX and US*

Ruple S. Laughlin, MD

**1:45 pm:** *The Latest in NMJ Disorders*

Karissa Gable, MD

**2:15 pm:** *Breakthroughs in Motor Neuron Disease*

James D. Berry, MD, MPH

1.50  
CME/CEU



01:15 pm - 02:45 pm	<b>Myalgia and Muscle Stiffness: Approach and Management - Part 2</b> <i>Grand Sonoran J-K</i>
Session	Classify and identify causes of muscle pain and stiffness, identify and manage stiff person syndrome and peripheral nerve hyperexcitability, and evaluate for and treat myofascial pain syndrome and fibromyalgia.
1.50 CME/CEU	<p><b>1:15 pm: Stiff Person Syndrome &amp; Peripheral Nerve Hyperexcitability</b> Goran Rakocevic, MD</p> <p><b>2:35 pm: Update on Myofascial Pain Syndrome and Fibromyalgia</b> Erik R. Ensrud, MD</p>
01:15 pm - 02:45 pm	<b>Neuromodulation in Pain Management</b> <i>Grand Sonoran C-D</i>
Session	Review basic concepts, benefits, and clinical applications of neuromodulation in pain management.
1.50 CME/CEU	<p><b>1:15 pm: Introduction</b> Monica J. Carrion-Jones, MD</p> <p><b>1:20 pm: Everything You Wanted to Know About Neuromodulation but Never Asked</b> Monica J. Carrion-Jones, MD</p> <p><b>1:50 pm: Clinical Applications, Benefits, and Case Presentations</b> Emanuel Gage, MD</p>
01:15 pm - 02:45 pm	<b>NM Video Cases</b> <i>Grand Sonoran F</i>
Session	Improve clinical skills based on watching videos of real cases; update knowledge on the presented topics (diagnosis and management); and become familiar with conducting effective virtual clinical visits.
1.50 CME/CEU	<p>Aziz Shaibani, MD</p> <p>Thy P. Nguyen, MD</p>

01:15 pm - 02:45 pm	<b>Update on ALS: Delivering a Diagnosis, Ventilatory Management, Multidisciplinary Care, and Home Care</b> <i>Grand Sonoran H-I</i>
Session	Detail how to deliver a diagnosis, initiate first line interventions for ventilatory care, coordinate multidisciplinary care, and order in home health care.
1.50 CME/CEU	<p><b>1:15 pm: Introduction</b> Bjorn E. Oskarsson, MD</p> <p><b>1:20 pm: Delivering a Diagnosis</b> Molly Kilpatrick, MD</p> <p><b>1:40 pm: Ventilatory Management</b> Christopher Lee, MD, MPH</p> <p><b>2:10 pm: ALS: Optimizing Interprofessional Care</b> Ileana Howard, MD</p> <p><b>2:40 pm: Home Health</b> Bjorn E. Oskarsson, MD</p>
03:45 pm - 05:15 pm	<b>Approach to Muscle Channelopathies and Their Management</b> <i>Grand Sonoran J-K</i>
Session	Articulate the causes of muscle channelopathies and classify them based on the ion channels involved, diagnose various forms of muscle channelopathies based on their clinical presentation and EDX characteristics, manage myotonic disorders by treating muscle stiffness and addressing systemic involvement in myotonic dystrophies, and manage periodic paralyses by preventing attacks and aborting attacks of paralysis.
1.50 CME/CEU	<p><b>3:45 pm: Periodic Paralysis</b> Mohammad K. Salajegheh, MD</p> <p><b>4:25 pm: Nondystrophic Myotonia</b> Jaya R. Trivedi, MD</p>

# Friday | Nov. 3

03:45 pm -  
05:15 pm

Session

## Approach to Muscle Diseases Based on Clinical Phenotype - Vignette Based

*Grand Sonoran H-I*

Recognize clinical clues facilitating diagnosis of inherited and acquired muscle disease in adults and children, review laboratory tests crucial for diagnosis of specific muscle disorders, and recognize how to integrate clinical and laboratory findings to prevent diagnostic errors.

**3:45 pm:** *Inherited Muscle Disorders in Adults*  
Margherita Milone, MD, PhD

**4:15 pm:** *Acquired Muscle Diseases in Adults*  
Anahit C. Mehrabyan, MD

**4:45 pm:** *Vignette Based Pediatric Muscle Disorders*  
Partha S. Ghosh, MD

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## Hot Topics in NM Literature - Part 2

*Grand Sonoran E*

Appraise several impactful findings in NM literature over the past year; recognize the clinical value of these studies and their impact to NM patients (EDX and sonographic methods, hereditary and acquired myopathy evaluation, peripheral neuropathy testing and treatment, motor neuron disease understanding, and NMJ disorder advancements); describe hot topics and groundbreaking work in these areas of NM medicine; and integrate emerging knowledge into clinical practice.

**3:45 pm:** *Introduction*  
Ruple S. Laughlin, MD

**3:50 pm:** *Recent Highlights in Peripheral Nerve Literature*  
Michelle L. Mauermann, MD

**4:30 pm:** *Updates in Myopathy: Hereditary and Acquired*  
Grayson Beecher, MD

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## Nerve Transfer Surgery: Where Surgeons and EDX Physicians Come Together to Restore Function

*Grand Sonoran G*

Describe how nerve transfers have changed the management of peripheral nerve injuries, summarize important advances in surgical treatment of nerve injuries that are on the horizon, and demonstrate a working knowledge of how EDX studies can be used to inform surgical management of nerve injuries.

**3:45 pm:** *Introduction*  
Lawrence R. Robinson, MD

**3:50 pm:** *How Nerve Transfers Have Changed the Treatment of Nerve Injuries*  
Susan Mackinnon, MD

**4:35 pm:** *How EDX Informs Surgical Decision Making for Nerve Transfers*  
Lawrence R. Robinson, MD

**1.50**  
CME/CEU

03:45 pm -  
05:15 pm

Session

## Optimizing the Role of APPs in NM Practice

*Grand Sonoran C-D*

Craft an on-the-job training plan for APPs entering neurologic practice; determine strategies for tracking APPs' clinical competency in real time to match their responsibilities with their skills and strengths; identify multiple MD/APP shared practice models that maximize productivity, promote retention, and allow APPs to practice at the top of their license; and develop a team-based approach to improve patient experience and increase access to NM care.

**3:45 pm:** *Craft an on-the-job Training Plan for APPs Entering Neurologic Practices*  
Andrew H. Dubin, MD, MS

**4:05 pm:** *Defining and Tracking APP's Clinical Competencies*  
Christopher Doughty, MD

**4:25 pm:** *Identify Multiple MD/APP Shared Practice Models That Maximize Productivity, Promote Retention, and Allow APPs to Practice at the Top of Their License*  
Margaret Naclerio, PA-C

**4:45 pm:** *Develop a Team-Based Approach to Improve Patient Experience and Increase Access to NM Care*  
Deena Rodney, APRN

**1.50**  
CME/CEU

## Workshop

### **You Make the Call: An Interactive Approach to EMG Waveform Recognition Skills - Basic**

Identify the firing patterns of different types of EMG waveforms, identify the characteristics of a variety of normal and abnormal spontaneous waveforms, recognize normal and abnormal patterns of recruitment of MUAPs, and recognize and understand the significance of the changes in morphology of MUAPs in diseases. Includes audience participation and videos of EMG waveforms.

This is a large group workshop open to physicians only.

**1.50 CME**

Devon I. Rubin, MD

## Workshop

### **You Make the Call: An Interactive, Multimedia Approach to Improving EMG Waveform - Advanced**

Identify the characteristics of a variety of uncommon abnormal spontaneous waveforms, recognize normal and abnormal patterns of recruitment of MUAPs, and recognize and understand the significance of subtle or complex changes in morphology of MUAPs in diseases. The workshop includes audience participation and video examples of EMG waveforms.

This is a large group workshop open to physicians only.

**1.50 CME**

Devon I. Rubin, MD



# Saturday | Nov. 4

08:00 am -  
09:30 am

Session

## Autoantibodies in Peripheral Neuropathies: Recent Updates

Grand Sonoran F

Review recent literature about autoantibodies associated with peripheral neuropathies, and recognize clinical presentation to guide and interpret autoantibody test results in peripheral neuropathy.

### 8:00 am: Introduction

Pritikanta Paul, MBBS, MD

### 8:05 am: Autoimmune Nodopathies and Other Seropositive Demyelinating Neuropathies

Divyanshu Dubey, MBBS

### 8:30 am: Phenotypic Association of Autoantibodies Associated With Axonal Neuropathies

Pritikanta Paul, MBBS, MD

### 8:55 am: Autoantibody Testing in Small Fiber and Autonomic Neuropathies

Srikanth Muppidi, MD

1.50  
CME/CEU

08:00 am -  
09:30 am

Session

## Evolving Therapeutic Landscape of MG Targeted Therapies

Grand Sonoran J-K

The treatment landscape in MG has rapidly evolved in recent years wherein broad, non-specific, slow-acting, and poorly tolerated treatments are becoming less desirable as targeted, fast-acting, and well-tolerated options become available.

Identify specific disease mechanisms involved in the pathogenesis of MG therapies in clinical trials; discuss data from recent clinical trials with targeted therapies; and discuss the possibilities, challenges, and conflicts related to concomitant use of traditional and new therapies.

This session will complement the session on Clinician's Approach to MG Therapies presented on Saturday, November 4, 10:00 - 11:30 am.

### 8:00 am: Disease Mechanisms and Treatment Targets in MG

Ali A. Habib, MD

### 8:25 am: Novel Therapies for MG: Where Do They Fit In?

Pushpa Narayanaswami, MD

### 8:50 am: Efficacy and Safety of Novel MG Therapies: Recent Clinical Trials

Shruti Raja, MD

1.50  
CME/CEU

08:00 am -  
09:30 am

Session

## Neuropathies in POTS and Long COVID Dysautonomia

Grand Sonoran H-I

Discuss how to assess, diagnose, and treat autonomic dysfunction and autonomic neuropathies in postural orthostatic tachycardia syndrome (POTS) and long COVID from three leading experts and review updates on the latest research in POTS.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through joint providership of AANEM and Dysautonomia International. The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

### 8:00 am: POTS 101

David S. Saperstein, MD

### 8:25 pm: Screening for Small Fiber Neuropathies and Underlying Pathology in POTS

Kamal R. Chémali, MD

### 8:50 pm: Research Updates on POTS and Long COVID Dysautonomia

Tae Hwan Chung, MD

1.50  
CME/CEU

08:00 am -  
09:30 am

Session

## New Developments in EDX and RX for Periodic Paralysis

Grand Sonoran C-D

Review the pathophysiology of depolarization-induced weakness in periodic paralysis as a paradigm for improving diagnosis and management, describe new advances in EDX based on muscle velocity recovery cycles, summarize new developments in pharmacologic management of episodic weakness, and discuss gene therapy considerations and show feasibility in pre-clinical studies.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through joint providership of AANEM and Periodic Paralysis Association. The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

### 8:00 am: Introduction

Steve C. Cannon, MD, PhD

### 8:05 am: Muscle Velocity Recovery Cycles in Periodic Paralysis: A Potential Biomarker and Deep Phenotyping Tool That can be Applied From Bench to Bedside

Karen Suetterlin, MBBS PhD

### 8:45 am: Therapeutics Under Development for Periodic Paralysis

Steve C. Cannon, MD, PhD

1.50  
CME/CEU

# Saturday | Nov. 4

08:00 am -  
09:30 am

Session

## Updates in Neuralgic Amyotrophy, Including Perspectives From a Novel Multidisciplinary Clinic

Grand Sonoran E

Describe updates in the diagnosis, pathogenesis, workup, and management of neuralgic amyotrophy, including: identifying hereditary, inflammatory, or environmental triggers for the disorder; recognizing the clinical presentation of neuralgic amyotrophy; implementing a targeted physical examination and EDX evaluation; describing the imaging findings on magnetic resonance neurogram and NMUS evaluation; outline rehabilitative and surgical management strategies for those with persistent disability, including indications and strategies for surgical intervention for torsional lesions, and adaptive orthotic and therapeutic techniques for patients who have developed altered motor programming; discuss the benefits of a patient-centered program with motivational interviewing; summarize perspectives from a novel multidisciplinary clinic and future directions for research, including description of patient vignettes and outcomes; discuss focused interviews aimed to evaluate the patient journey to diagnosis, as well as patient feedback from the clinic; and identify components of the program that may be adopted at other sites.

**8:00 am:** *Introduction*  
Joelle Gabet, MD

**8:05 am:** *Examination Pearls, EDX and US Findings in Neuralgic Amyotrophy*  
Michael C. Munin, MD

**8:30 am:** *Rehabilitative and Surgical Management Strategies for Those With Persistent Disability From Neuralgic Amyotrophy*  
Joelle Gabet, MD

**8:55 am:** *Perspectives From a Novel Multidisciplinary Clinic and Future Directions for Research*  
Noriko Anderson, MD, MPH

1.50  
CME/CEU

08:00 am -  
09:30 am

Session

## US-Guided Nerve Blocks and Hydrodissection

Grand Sonoran G

Review resources on how to best evaluate nerves, as well as tips for equipment, optimal patient positioning, and needle guidance for nerve blocks and hydrodissection under sonography; describe basic step-by-step guidance for optimal medication placement; and demonstrate a patient case in which the block was utilized (lower extremity nerve blocks, upper extremity nerve blocks, uncommon nerve blocks).

A subject will be available along with a high-frequency US machine to demonstrate real-time evaluation of each nerve.

1.50  
CME/CEU

**8:00 am:** Lester S. Duplechan, MD

10:00 am -  
11:30 am

Session

## Case-Based Session - Using US for Nerve Injuries

Grand Sonoran H-I

Review basic pathophysiology of peripheral nerve injury secondary to trauma and describe US correlations, review individual case examples of US findings in nerve trauma, and detail how these findings may change the patient's diagnosis and/or management, especially with regard to surgical planning. Attendees should be able to identify situations where US may provide important clinical information, recognize common features on US reflective of nerve injury, and interpret sonographic evidence in the context of the patient's clinical presentation and EDX findings.

**10:00 am:** *US for Traumatic Nerve Injuries and Its Utility in Surgical Planning*  
Sarah Smith, MD

**10:20 am:** *Case-Based Session - Using US for Nerve Injuries*  
Sarada Sakamuri, MD

**10:40 am:** *US Evaluation of Peripheral Nerve Injuries: A Surgeon's Perspective*  
TJ Wilson, MD

1.50  
CME/CEU

**11:00 am:** *Case Presentations*  
James B. Caress, MD

## 10:00 am - 11:30 am **Clinician's Approach to MG Therapies** *Grand Sonoran J-K*

Session

Review the role of various conventional and newer therapies in patients with MG and how to optimally use these therapies in clinical practice.

This session is complemented by Evolving Therapeutic Landscape of MG: Targeted Therapies presented on Saturday, Nov. 4, 8:00 - 9:30 am.

**10:00 am:** *Traditional Immunosuppressive Agents in MG*  
Nicholas J. Silvestri, MD

**10:25 am:** *Complement Inhibition in MG*  
Srikanth Muppidi, MD

**10:50 am:** *FcRn Inhibition and B Cell Therapies in MG*  
Neelam Goyal, MD

**1.50**  
CME/CEU

## 10:00 am - 11:30 am **Novel Therapeutic Approaches for ALS: From Bench to Bedside** *Grand Sonoran F*

Session

Recognize the expectation and unmet needs for ALS treatment; discuss the preclinical data in ALS supporting novel therapeutic approaches, existing data on trials, and the challenges and opportunities for these approaches; and explain recent progress in trial designs and pharmacological therapies. Novel therapeutics and improving study design will be discussed including use of antisense oligonucleotides for familial ALS, cell therapy, recently approved drugs (Relyvrio and edaravone), and drugs under development. Review recently completed and ongoing clinical trials for familial ALS focusing on ASOs for SOD1, FUS, C9, ATXN-2; lessons from observational trials for pre-symptomatic gene carriers (PreFALS study, PREVENT ALS study which is the merger of DIALS at MGH/WashU and ALS Families at Columbia, ALL-FTD) and how these our inform knowledge of pre-symptomatic/prodromal ALS; and discuss movement towards preventative therapies for familial ALS (ATLAS trial of tofersen).

**10:00 am:** *Novel Therapeutic Approaches for ALS - From Bench to Bedside: Challenges, Unmet Needs, and Future Prospectives*  
Nizar Souayah, MD

**10:25 am:** *New Developments in ALS Trial Design: What Have Recent Positive and Negative Trials Taught Us?*  
Jeremy M. Shefner, MD, PhD

**10:50 am:** *Familial ALS: Recent Advances in Targeted Therapies and Progress Towards Preventing ALS*  
Mark Garret, MD

**1.50**  
CME/CEU

## 10:00 am - 11:30 am **Paraproteins and Peripheral Neuropathy** *Grand Sonoran E*

Session

Review myeloproliferative disorders that create monoclonal proteins and how to interpret test results for these disorders; discuss the relationship of paraproteins with peripheral neuropathies; and summarize the oncology and neurology workup and treatment of paraprotein associated peripheral neuropathies.

**10:00 am:** *Overview of Myeloproliferative Disorders Associated With Paraproteins*  
Sascha Tuchman, MD

**10:25 am:** *IgM Paraprotein Associated Neuropathies*  
Karissa Gable, MD

**10:50 am:** *POEMS and AL Amyloidosis Associated Neuropathy*  
Rebecca Traub, MD

**1.50**  
CME/CEU

## 10:00 am - 11:30 am **Pediatric Brachial Plexus** *Grand Sonoran C-D*

Session

This course will go through the process of evaluating a neonate in the multidisciplinary clinic of Michigan for brachial plexus. It will include the initial assessment with Neurology, Neurosurgery, Physical Medicine and Occupational therapy to determine which tests need to be done, i.e. EMG, MRI. Then we will show how that information is used to determine if a baby needs surgery or not and which surgery is the most helpful in getting the most use out of the arm. We will follow a real case to highlight this procedure

This is a technologist-focused session. Anyone who has interest in this topic is welcome to attend.

**10:00 am:** *Introduction*  
Teresa Spiegelberg, CNCT, R.NCS.T., R.EEGT, BS

**10:05 am:** *Brachial Plexus Management*  
Miriana Popadich, RN, BSN, MSN, NP-C

**10:25 am:** *Surgical Management of Neonatal Brachial Plexus Palsy*  
Whitney Muhlestein, MD

**10:45 am:** *Why Do EMG?*  
Ann A. Little, MD

**11:00 am:** *Therapy Strategies for Brachial Plexus Palsy*  
Denise Justice, OTRL

**1.50**  
CME/CEU

# 2023 Achievement Awards

AANEM is pleased to recognize the recipients of the 2023 AANEM Achievement Awards. Join us in congratulating these individuals on their outstanding contributions to NM and EDX medicine. All award recipients will be recognized on Friday, Nov. 3 at the beginning of the Plenary 3 session.

## Lifetime Achievement Award - John C. Kincaid, MD

AANEM's Lifetime Achievement Award is the highest honor bestowed by AANEM, and is given to members who are recognized as major contributors in the fields of NM and EDX medicine. John C. Kincaid, MD, is honored for his lifelong dedication to research, patient care, advocacy, and education.

Dr. Kincaid embarked on his professional medical journey at Indiana University School of Medicine, where he completed his medical degree, internship, and neurology residency. After completing a fellowship in EMG at Mayo Graduate School of Medicine in Rochester, Minnesota, he returned to his roots in Indiana and dedicated his career to the advancement of NM and EDX medicine.

Dr. Kincaid has held numerous hospital appointments at Indiana University Hospitals and Indiana University Health, including the Kenneth L. and Selma G. Earnest Professor of Neurology. Currently, he continues to serve as an attending neurologist for patients with NMDs; is in the EMG lab 4.5 days per week; and is involved with education of medical students, neurology and PM&R residents, and neurophysiology fellows on a daily basis.



He also served as the medical expert for disability cases for the Social Security Administration for 35 years. "I am 7 years past when I could have retired from Indiana University, but the reward of being involved in teaching high-quality EMG and the day-to-day involvement in the advances in medical knowledge are too engaging to walk away from," he said.

Dr. Kincaid has also made significant contributions to the field through his publications in notable peer-reviewed journals and comprehensive textbooks, including *Practical Electromyography 3rd Edition* and *Neuromuscular (Rehabilitation Medicine Quick Reference) 1st Edition*.

Dr. Kincaid has been an important leader within AANEM for decades. He has served in nearly every role across the organization, including as director, historian, and president of the AANEM Board of Directors and director, secretary, and chair of the ABEM Board of Directors.

"I am very honored to receive this award," he said. "AANEM has been my professional society home base for 43 years. The learning and professional growth opportunities the organization offered me shaped my career in a major way."

## Distinguished Physician Award - Bassam A. Bassam, MD

Bassam A. Bassam, MD, is honored for his exceptional contributions to patient care, research, and education in the fields of NM and EDX medicine.

Dr. Bassam's journey in medicine began at Aleppo University in Syria, where he completed his medical degree. He went on to pursue a neurology residency at Wayne State University (WSU) and a NM fellowship at WSU and Mayo Clinic. After completing his training, Dr. Bassam was soon appointed as the director of neurology at Wayne County General Hospital, affiliated with the University of Michigan.

Dr. Bassam has been a tenured professor of neurology and director of the EMG & NMD laboratory since 1985, and briefly served as interim chairman for the neurology department at the University of South Alabama.



Dr. Bassam developed a passion for NM medicine early in his career and has found professional satisfaction across clinical, research, and educational work. "I have found that direct care of patients with NMDs is the best way for understanding illness, motivating research, and advancing the field," he said.

Dr. Bassam has been an active member of AANEM since 1981. "My involvement with AANEM has been an indispensable opportunity that's shaped my career in NM and EDX medicine, for both academic achievements and quality patient care," he said. "I am very thankful and appreciative of the great job and continuous effort of all the AANEM staff that has helped AANEM to remain our top NM and EDX medicine association."



### Distinguished Researcher Award - David R. Cornblath, MD

David R. Cornblath, MD, is honored for his contributions to the study of peripheral neuropathies and his extensive research in the fields of NM and EDX medicine.

Dr. Cornblath received his medical degree from Case Western Reserve University, and continued his training with an internship at University Hospitals in Cleveland, Ohio, followed by a neurology residency at the Hospital of the University of Pennsylvania. His passion for NM medicine led him to become a clinical fellow of the Muscular Dystrophy Association at the Peripheral Nerve Morphology Laboratory. Later, he joined the neurology faculty at Johns Hopkins, where he served as director of the Neurology EMG Laboratory.

Currently retired, he holds the title of professor emeritus of neurology at Johns Hopkins. Even in retirement, Dr. Cornblath continues to consult, serving on safety monitoring boards and clinical trial development programs.

Dr. Cornblath co-authored the book *Diagnosis and Management of Peripheral Nerve Disorders* and has written over 200 articles and chapters on various NMDs, including GBS, CIDP, ALS,

NMDs associated with HIV infection, diabetic neuropathy, and painful neuropathies. He also served as the Editor-in-Chief of the *Journal of Peripheral Nervous System*.

One of Dr. Cornblath's most notable endeavors was the development of criteria for the diagnosis of GBS in collaboration with Dr. Arthur Asbury. Their paper, *Assessment of Current Diagnostic Criteria for Guillain-Barré Syndrome*, has been widely cited and served as the basis for clinical trials and studies in this field.

Dr. Cornblath is also the co-inventor, alongside Vinay Chaudhry, MD, of the Total Neuropathy Score®, a validated measure of peripheral nerve function.

Dr. Cornblath's long-standing affiliation with AANEM dates back to 1982. Receiving the Distinguished Researcher Award from AANEM came as a surprise to Dr. Cornblath, who expressed deep gratitude and honor. He said, "I was quite surprised. When I looked at the list of the past people, it was a very nice group to join. It's a lovely honor and a privilege to be considered in that class."



### Jun Kimura Outstanding Educator Award - Amanda C. Peltier, MD, MS

Amanda C. Peltier, MD, MS, is honored for her numerous contributions to advancing medical education in the fields of NM and EDX medicine.

Dr. Peltier completed her medical degree at The Ohio State University, followed by a neurology residency and master's degree in clinical research design and statistical analysis at the University of Michigan. She also completed a NM fellowship, specializing in EMG, skin biopsy, and autonomic testing.

Dr. Peltier currently serves in many roles at Vanderbilt University Medical Center (VUMC). She is chief of the division of NMDs, full professor of neurology and medicine, director of the MDA/ALS clinic, and the site principal investigator for ALS and NM clinical trials at VUMC. She also serves as the fellowship director for the NM program at Vanderbilt University and is a valued

member of the Vanderbilt Autonomic Disorders Center and the Vanderbilt Amyloid Multidisciplinary Program. Apart from her responsibilities as a fellowship director, she actively participates in the Residency Recruitment Committee for the department of neurology and serves as the associate vice chair of faculty affairs.

Dr. Peltier has been an active member of AANEM since 2002. "The AANEM has a huge role in education support," she said. "It is a fantastic organization, and I have enjoyed working with AANEM for the last 20 years. It has helped me in my role as a fellowship director especially."

Dr. Peltier shared, "Thank you all very much for this award. I was frankly surprised and very, very honored. I hope that I try to pass on all of the knowledge that I learned from my mentors."



### Ernest Johnson Outstanding Educator Award - Monika Krzesniak-Swinarska, MD

Monika Krzesniak-Swinarska, MD, is honored for her unwavering dedication to education in the fields of NM and EDX medicine.

Dr. Krzesniak-Swinarska graduated from the Medical University of Gdansk, Poland, and completed a PM&R residency at the Medical College of Wisconsin in Milwaukee. Following her residency, Dr. Krzesniak-Swinarska played an instrumental role in developing a MSK US course for PM&R residents at the Medical College of Wisconsin.

Dr. Krzesniak-Swinarska pursued a NM medicine fellowship at Wake Forest School of Medicine. Following her fellowship, she joined the neurology department at the University of New Mexico School of Medicine in Albuquerque, where she currently serves as associate professor of PM&R, NM medicine, and neurology and holds a secondary appointment in the department of orthopaedics & rehabilitation. She is also director of the Adult MDA Care Center and director of the EMG laboratory.



When asked about her key motivations, Dr. Krzesniak-Swinarska explained, “First, I believe that the best way to learn is to teach. By teaching, one must learn the core material in great depth and be able to make it relevant to students’ lives in today’s society. My second major motivation for excellent teaching is that I help people learn to improve themselves. Additionally, I believe that a good teacher is one who is not only competent in their field but is also always striving to learn more. In my opinion, educators who recognize that they do not know everything, but who also aim to constantly improve their own knowledge, can better relate to students because they continue to be students themselves.”

Dr. Krzesniak-Swinarska has been an active member of AANEM since 2010. Dr. Krzesniak-Swinarska said, “I am grateful to AANEM for this recognition and humbled by the award. I admired Dr. Johnson’s leadership in academic PM&R, and I strongly believe in Ernie’s ‘patient-first’ teaching philosophy. This award inspires me to continue my educator work with more passion and enthusiasm.”

### Scientific Impact Award - Elie Naddaf, MD

Elie Naddaf, MD, is recognized for his contribution as senior author of *Survival and Associated Comorbidities in Inclusion Body Myositis*, which appeared in the September 2021 issue of *Rheumatology*. Co-authors include Shahr Shelly, Jay Mandrekar, Alanna M. Chamberlain, E. Matthew Hoffman, Floranne C. Ernst, and Teerin Liewluck.

This article is highly relevant to physicians as it sheds light on the prognosis of patients with IBM and identifies the complications and comorbidities associated with the disease.

Dr. Naddaf completed a neurology residency at the University of Wisconsin Hospitals and Clinics in Madison, followed by a fellowship in NM medicine at Mayo Clinic in Rochester, Minnesota. He is currently a neurologist specializing in NMDs and pursuing a master’s degree in clinical and translational science, concentrated on clinical trial design through the Mayo Graduate School.



Dr. Naddaf has been a member of AANEM since 2014. He believes AANEM, as well as ANF, play a vital role in supporting researchers. “AANEM is a major platform for NM and EDX education via the annual meeting, online educational materials, podcasts, and other educational opportunities. It also offers a nurturing, friendly environment for researchers, especially early-career ones, to present their work and receive constructive, nonjudgmental feedback from experts in the field. ANF, which uses 100% of donations to support researchers, also plays a major role advocating for and advancing NM medicine research,” he said. “I feel honored, grateful, and very happy to receive this recognition.”

Dr. Naddaf extends his thanks to the AANEM Board of Directors and Awards Committee for selecting his publication and acknowledges the colleagues in neurology, rheumatology, biostatistics, and Rochester Epidemiologic Project who contributed to the project.

### Scientific Impact Award - Colin K. Franz, MD, PhD

Colin K. Franz, MD, PhD, is recognized for his contribution as senior author of *The Distribution of Acquired Peripheral Nerve Injuries Associated With Severe COVID-19 Implicate a Mechanism of Entrapment Neuropathy: A Multicenter Case Series and Clinical Feasibility Study of a Wearable, Wireless Pressure Sensor*, published in the October 2022 issue of *Journal of NeuroEngineering and Rehabilitation*. Co-authors include Nikhil K. Murth, George R. Malik, Jean W. Kwak, Dom D'Andrea, Alexis R. Wolfe, Ellen Farr, Melanie A. Stearns, Swati Deshmukh, Jinny O. Tavee, Fang Sun, Kevin N. Swong, Leslie Rydberg, R. James Cotton, Lisa F. Wolfe, James M. Walter, John M. Coleman III, and John A. Rogers.

This article emphasizes the risk and distribution of peripheral nerve injuries among patients hospitalized with severe COVID-19, and highlights the critical need for protecting peripheral nerves in these individuals.



Dr. Franz earned a PhD at Dalhousie University in anatomy and neuroscience focused on peripheral nerve injury and regeneration, specifically studying different motor nerve subtypes. His interest in translational research and medicine led him to pursue a medical degree from the University of Calgary. He is currently the director of the EDX laboratory at the Shirley Ryan AbilityLab hospital and a physician in the Lois Insolia ALS Clinic at Northwestern Memorial Hospital in Chicago.

An active member of AANEM since 2017, Dr. Franz serves on the Research Committee and the PM&R Membership Task Force. "It's an honor to receive this award from the AANEM since it's the organization that best represents my peers and my medical subspecialty," Dr. Franz concluded. "There is no greater honor than to be recognized by your peers, including so many colleagues who you look up to and inspire you."

### Honorary Member Award - Susan E. Mackinnon, MD

Susan E. Mackinnon, MD, is recognized for her achievements in the area of nerve transfer procedures and outstanding achievements in clinical care, community service, research and teaching. AANEM's Honorary Member Award is granted to nonmember physicians or scientific investigators who are major contributors to the field of NM, EDX, neurophysiology, or MSK disease by virtue of teaching, research, and scholarly publications.

Dr. Mackinnon received her medical degree from Queens University and completed a residency in plastic and reconstructive surgery and research fellowship in neurosurgery at the University of Toronto. She continued to develop her specialty and competed a fellowship in hand surgery at the Raymond Curtis Hand Center, Union Memorial Hospital.

Dr. Mackinnon is the Minot Packer Fryer Professor of Surgery at the Washington University School of Medicine in St. Louis. She pioneered the development of surgical nerve transfers and a new method of successfully treating patients with severe injuries affecting peripheral nerves and the brachial plexus, and she has trained many surgeons nationally and internationally in the use of nerve transfer techniques. Dr. Mackinnon consistently collaborates with EDX physicians to assess patients both before and after nerve transfer procedures.



Dr. Mackinnon has received numerous accolades in her career thus far, including the Jacobson Innovation Award from the American College of Surgeons; membership in the National Academy of Medicine; Clinician of the Year Award, Research Achievement Award for Basic Science, and Distinguished Fellow Award from the American Association of Plastic Surgeons; and served as president of the AAPS, AAHS, PSRC, and ASPN. She has also been recognized with a Distinguished Faculty Award - Distinguished Educator from the Washington University School of Medicine for her dedication to surgical education and commitment to mentoring surgical trainees, postdoctoral students, residents, and fellows. She has helped hundreds of mentees follow their passions, while serving as division chief, becoming a world-renowned hand surgeon, and conducting groundbreaking research on nerve allotransplantation and nerve transfer.

Dr. Mackinnon was surprised and honored to receive this award. She said, "When you're recognized by a group that is not in your academic family, it's extra special. So to be recognized by a nonsurgical specialty that I care very much about is a true honor."

### Outstanding Service Award - Teresa Spiegelberg, CNCT, R.NCS.T., R.EEG.T, BS

Teresa Spiegelberg, CNCT, R.NCS.T., R.EEG.T, BS, has been awarded the inaugural Outstanding Service Award for her contributions to the fields of NM and EDX medicine and dedicated service to patients, medical education, and AANEM.

Ms. Spiegelberg has been a technologist at the University of Michigan EMG lab for decades. Known as the unofficial “lead technologist” in her lab, Ms. Spiegelberg directs testing of residents and fellows and manages the educational weekly NM lecture series at the University of Michigan. She is also a critical part of the neurosurgical evaluation of infants with neonatal brachial plexus palsy and adults with various peripheral nerve lesions.

Ms. Spiegelberg has been an AANEM member since 2010. “I think AANEM offers a wonderful place for technologists at all levels to converse and learn from one another,” she

said. “Participating in hands-on workshops allows people to not only learn from the instructor, but also to share their approaches with the instructor. I think we should all be open to having different techniques shared with us. I recall a smart person once saying to me, ‘no one of us is smarter than all of us together.’”



Ms. Spiegelberg feels honored to be awarded the inaugural Outstanding Service Award from AANEM. “I am extremely honored to be the first recipient of this award, especially considering the fact that I know so many wonderful technologists involved in the AANEM, like Candy Dolan, Peggy Neal, and Jerry Morris to name just a few among the many who have provided great service not just to the AANEM, but in their local area as well,” she said. “To me, getting this award shows that when you love and care about doing the best you can at your profession, others appreciate you as well.”

### Public Recognition Award - Brooke Eby

Brooke Eby has been awarded the Public Recognition Award for her outstanding dedication to promoting awareness of muscle and nerve disorders through social media. This award is given to public figures, celebrities, or entities that have made extraordinary contributions toward increasing public awareness.

In March 2022, at the age of 33, Brooke Eby received a life-altering diagnosis: ALS. Now 34 years old, Brooke has transformed her diagnosis into a powerful platform for awareness and advocacy.

She decided to share her ALS journey publicly after witnessing actress Selma Blair’s impact in raising awareness for multiple sclerosis. She realized the need for a relatable “face” for ALS and began creating humorous videos on TikTok to gauge interest. The response was overwhelming, inspiring her to build a community where people feel comfortable asking questions and discussing terminal diagnoses openly.

Scientific research on NMDs, including ALS, is crucial to find treatments and, ultimately, a cure. Brooke often states, “ALS is not incurable, it’s underfunded,” and the only hope lies in

advancing research. She compares her situation to being in a car driving toward a cliff, with research being the only way to slow down or stop the inevitable outcome.

In her relentless pursuit to raise awareness, Brooke urges readers to donate to the American Neuromuscular Foundation. Increased financial support will accelerate progress and bring hope to countless individuals living with these diseases.



“I’m so grateful to receive AANEM’s Public Recognition Award,” Brooke said. “I consider any work in the fight against ALS to be award-worthy, so thank you for honoring my efforts this year. I hope to make a difference for the future of those fighting for ALS.” She is grateful to her friends, boyfriend, and family for their unwavering support and the laughter they bring into her life.

Through laughter and open conversations, Brooke believes we can drive awareness, funding, and hope for a brighter future for those affected by ALS and related diseases. She invites everyone to join her on her journey by following her story on social media (@limpbroomkit), where she says, “We’ll talk about ALS, but I promise that we’ll laugh along the way.”



# 2023 Abstract Awards

AANEM's abstract awards celebrate up-and-coming medical students, residents, and fellows who are beginning their careers, as well as experienced individuals who have conducted great research.

Congratulate all award winners during the Abstract Award Reception on Thursday, Nov. 2 from 5:15-6:45 pm in the Poster Hall. Abstract authors will also be available during select abstract poster sessions:

**Session I | Thursday, Nov. 2 | 6–6:30 pm**

**Session II | Friday, Nov. 3 | 9:30–10 am**

**Session III | Friday, Nov. 3 | 3–3:30 pm**

All abstracts are published in the October issue of *Muscle & Nerve*.



## Golseth Young Investigator Award

The Golseth Young Investigator Award, honoring AANEM founding member Dr. James Golseth, is given to the best research submitted by a young physician to the AANEM Annual Meeting.

**Winner: Michael Skolka, MD**

The Utility of Electrodiagnostic Testing in Rhabdomyolysis in the Era of Next Generation Sequencing (*Abstract #1*)



Dr. Skolka, a NM fellow at Mayo Clinic, explored the utility of EMG in rhabdomyolysis. His objective was to identify rhabdomyolysis patients with a high likelihood of myopathic EMG and to examine the correlation between EDX findings and the underlying etiology of the unprovoked rhabdomyolysis.

“We found that myopathic EMG occurred in approximately half of our rhabdomyolysis patients. Patients with weakness and elevated CK at baseline were more likely to have myopathic EMG, and most patients with myopathic EMG had non-metabolic myopathies instead of metabolic myopathies as an underlying etiology of rhabdomyolysis. Additionally, non-myopathic EMG did not exclude an underlying myopathy.”

One unexpected discovery was that the data supported evaluating patients for an underlying myopathy following unprovoked rhabdomyolysis even if they only had one episode of rhabdomyolysis, challenging the current clinical tendency to assess patients only after recurrent episodes. The team also designed an algorithm to guide healthcare providers in evaluating patients who have experienced an episode of unprovoked rhabdomyolysis.

“I want to sincerely thank all of my mentors at Mayo Clinic and at the AANEM, especially Dr. Teerin Liewluck as well as Drs. Margherita Milone, Ruple Laughlin, William Litchy, and Devon Rubin, who all helped with this project and who have guided me along the way in my training,” he said. “I wouldn’t be the physician and researcher I am today without the help of my colleagues and the support of my family and wife. This award goes to all of them as much as it goes to me.”



## Best Abstract Award

---

The Best Abstract Award is given to the first and presenting author of the best abstract submitted to the AANEM Annual Meeting.

### Winner: Jerry Mendell, MD

Long-Term Safety and Efficacy in Patients With Duchenne Muscular Dystrophy 4 Years Post-Treatment With Delandistrogene Moxeparvovec in a Phase 1/2a Study (*Abstract #2*)



Dr. Mendell's abstract reports the outcomes of a long-term, open-label, Phase 1/2a study (Study 101; SRP-9001-101; NCT03375164) evaluating the safety and functional outcomes 4 years post-treatment with delandistrogene moxeparvovec. Delandistrogene moxeparvovec (SRP-9001) is an investigational rAAV vector-based gene therapy, designed to compensate for missing dystrophin in DMD by delivering a transgene encoding SRP-9001 dystrophin, an engineered dystrophin protein retaining key functional domains of the wild-type protein.

Dr. Mendell concluded that delandistrogene moxeparvovec was well tolerated 4 years post-treatment. Functional assessments demonstrated long-term sustained stabilization of motor function that was clinically meaningful, at ages where functional decline would be expected based on natural history.

This study helped support the agent's biologics license application, and in June 2023, SRP-9001 was granted accelerated approval by the FDA for individuals with DMD ages 4-5. Emphasizing the transformative potential of this gene therapy research, Dr. Mendell said, "This accelerated approval is extremely important and really advances the field. It's the first time we'll have systemic gene therapy in the field for DMD."

Dr. Mendell is an attending neurologist at Nationwide Children's Hospital, the Dwight E. Peters and Juanita R. Curran Endowed Chair in Pediatric Research at the Abigail Wexner Research Institute, and professor of pediatrics and neurology at The Ohio State University.

### Runner-Up: Oksana Haiko, MD, PhD, ScD

The Role of Ultrasound in Diagnosis of Nerve Injury After Gunshot Wounds and Blast Injuries (*Abstract #3*)



As head of diagnostics at the Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine, Dr. Haiko and co-authors Liudmila Klymchuk, MD, and Roman Luchko, MD, PhD, investigated the US features of different types of nerve injuries resulting from gunshot wounds and blast injuries to enhance diagnostic capabilities and establish evidence-based treatment strategies.

Her research concluded that US can be leveraged as an objective and highly informative diagnostic tool for nerve injury after gunshot and blast injuries, allows early identification of injury severity, and helps guide surgical decision-making.

Looking ahead, Dr. Haiko plans to delve deeper into the study of US changes in nerves and muscles, and comparison with EMG data to further refine diagnostic approaches and advance treatment strategies for patients with nerve injuries.

"This was unexpected for all authors. We feel happy and very proud to receive the Best Abstract Runner Up from AANEM, one of the biggest and most famous associations dedicated to NM and EDX medicine," she said. "This award encourages us to work harder and generate new ideas and projects. We would like to thank the AANEM Abstract Committee which deemed our abstract worthy of the award."

## Technologist Best Abstract Award

---

The Technologist Best Abstract Award is given to the best research paper submitted by a technologist who has conducted and shared research to advance the science of NM and MSK diseases.

### Winner: Stephanie Harvey

A Survey of Nerve Conduction Technologist's Role in EMG Labs (*Abstract #4*)



Ms. Harvey is an EMG technologist in the department of neurology with McGovern Medical School at UTHealth Houston. Motivated by the busy environment of their EMG lab, Ms. Harvey and her team sought to explore the impact of nerve conduction technologists on productivity, as perceived by EMG physicians.

Their findings revealed that 76% of respondents believed the inclusion of nerve conduction technologists enabled them to see a greater number of patients. Emphasizing the value of these professionals in EMG labs, Ms. Harvey stated, “We hope that EMG labs recognize that nerve conduction technologists are an asset. Career growth and continuing education for nerve conduction technologists should be emphasized.”

She is grateful for the support of her colleagues, and thanked them for helping her learn about the science behind nerve conduction technologists. “My partner in the EMG lab, Yuri Salas, has taught me a lot and played a big role in my training. I work with a team of neuromuscular specialists, including Drs. Suur Biliciler, Kristin Brown, Thy Nguyen, Rajesh Gupta, Sri Sista, and Kazim Sheikh who are great at what they do and are always eager to answer any questions I have,” she said.

Ms. Harvey expressed surprise, honor, and newfound inspiration upon receiving the award. She said, “I feel very honored and inspired to win this award. It makes me feel excited about future projects and learning.”

## President's Research Initiative Award

---

The President's Research Initiative Award is given to up to 10 individuals who submitted the best abstracts related to the annual meeting plenary topic chosen by the AANEM President each year.

<b>Mohsen Ahmed, BS</b>	Are Neuromuscular Diseases Associated With a Greater Level of Neuro-Psychiatric Conditions? ( <i>Poster #13</i> )
<b>Abdullah Al Qahtani, MD, MPH</b>	Patient Reported Impact of Symptoms in Spinal Bulbar Muscular Atrophy ( <i>Poster #5</i> )
<b>Hala Elhabashy, MD</b>	Transcranial Direct Current Stimulation in Multiple Sclerosis: Exploring Novel Routes ( <i>Poster #8</i> )
<b>Ryan Floresca, BS</b>	Impact of Edaravone on the Amyotrophic Lateral Sclerosis Course at TTUHSC El Paso Clinic: A Prospective Cohort Study ( <i>Poster #11</i> )
<b>Naglaa Gadallah, MD</b>	Objective Prognostic Parameters for Management of Spasticity: Clinical, Electrodiagnostic, and Surgical Study ( <i>Poster #7</i> )
<b>Brendan McNeish, MD</b>	Chemotherapy-Induced Peripheral Neuropathy is Associated With Decreased Executive Functioning in Cancer Survivors ( <i>Poster #12</i> )
<b>Julia Shah, MD</b>	Assessing Rehab Needs in Children With Spinal Muscular Atrophy Status Post Onasemnogene Apeparvovec-Xioi ( <i>Poster #6</i> )
<b>Hallie Walsh, BA</b>	Virtual Exercise Group Programs for Rehabilitation of Veterans With Amyotrophic Lateral Sclerosis ( <i>Poster #9</i> )
<b>Adeel Zubair, MD</b>	Evaluation of Neuromuscular Provider Perceptions and Office Setup for Evaluating Patients With Disabilities ( <i>Poster #10</i> )

## Medical Student Research Award

---

The Medical Student Research Award encourages medical students to conduct research in NM and EDX medicine. Awards are given to medical students who are the first author and designated presenter on abstracts presented at the AANEM Annual Meeting.

<b>Afaaq Ahmed, BS</b>	Regional Disparities in Treatment Outcomes for Patients With Myasthenia Gravis Exacerbation ( <i>Poster #33</i> )
<b>Mohsen Ahmed, BS</b>	<ul style="list-style-type: none"><li>Are Neuromuscular Diseases Associated With a Greater Level of Neuro-Psychiatric Conditions? (<i>Poster #13</i>)</li><li>Performance of Academic and Non-Academic Centers in Treatment of Guillain-Barre Syndrome (<i>Poster #25</i>)</li><li>Outcomes for Patients With Neuromuscular Disease Following Invasive Neurological Procedures (<i>Poster #26</i>)</li></ul>
<b>Angela Ballesteros, BS</b>	The "Rogue Wave Sign" as an Indicator of an Entrapment Mononeuropathy: A Case Report ( <i>Poster #22</i> )
<b>Tyler Cook, MS</b>	An Ultra-Rare Genetic Cause of Global Developmental Delay and Severe Hypotonia ( <i>Poster #15</i> )
<b>Jonathan Espinosa, BSA</b>	A Case of Slowly Progressive Ascending Weakness After COVID-19 Vaccine ( <i>Poster #16</i> )
<b>Margarita Fedorova, BA</b>	Clinical and Diagnostic Features of Small Fiber Neuropathy With Fibroblast Growth Factor Receptor 3 Antibodies ( <i>Poster #17</i> )
<b>Huang He Ding</b>	The Provider's Perspective on Newer Therapeutics for the Treatment of Generalized Myasthenia Gravis: A Cross-Sectional Survey ( <i>Poster #32</i> )
<b>Kazim Jaffry, BA</b>	<ul style="list-style-type: none"><li>Urine Secretory Phospholipase A2 in Demyelinating Diabetic Distal Symmetric Polyneuropathy (<i>Poster #18</i>)</li><li>Comparing Mortality and Morbidity in Standard Treatment Protocols for Guillain-Barre Syndrome (<i>Poster #19</i>)</li><li>Temporal Changes in Trends and Outcomes for Multifocal Motor Neuropathy (<i>Poster #20</i>)</li><li>Identification of Trends and Clinical Outcomes in Pediatric Botulism (<i>Poster #21</i>)</li></ul>

<b>Marilyn Lu, BA</b>	Juvenile Myasthenia Gravis in North Texas: Clinical Features, Treatment Response, and Outcomes ( <i>Poster #30</i> )
<b>Lisa McReynolds, MBBCH</b>	What a Waste! (Of Thenar Muscle): A Service Improvement Audit ( <i>Poster #24</i> )
<b>Olivia Pakula, BA</b>	Clinical Disparities Between Caucasians and African Americans With Charcot-Marie-Tooth Disease Type 1A ( <i>Poster #29</i> )
<b>Jude Tunyi, BS</b>	Deep Brain Stimulation for the Management of AIFM1-Related Disabling Tremor: A Case Series ( <i>Poster #31</i> )
<b>Nikhita Valipe</b>	What is the Most Effective Use of Bisphosphonates to Optimise Bone Health in Patients With Duchenne Muscular Dystrophy? ( <i>Poster #23</i> )
<b>Nicole Zougheib, MBA</b>	Ultrasound as a Diagnostic Modality for Wrist Pain in a Nonverbal Patient With Autism Spectrum Disorder ( <i>Poster #28</i> )

## Residency and Fellowship Member Award

The Residency and Fellowship Member Award encourages young physician members to conduct research in NM and EDX medicine. Awards are given to residency and fellowship members who are the first author and designated presenter on abstracts presented at the AANEM Annual Meeting.

<b>Ian Ackers, DO, PhD</b>	A Tongue Twister: Tongue Weakness Due to Paraneoplastic Syndrome in Multiple Myeloma ( <i>Poster #62</i> )
<b>Adenike Adewuyi, MD, PhD</b>	<ul style="list-style-type: none"> <li>A Case of Post-Infectious Herpes Simplex Virus Type 1-Related Bibrachial Plexopathy (<i>Poster #56</i>)</li> <li>Obinutuzumab for the Treatment of Refractory Systemic Lupus Erythematosus Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy (<i>Poster #57</i>)</li> </ul>
<b>Hassan Alhussein, MD</b>	Atypical Pathological Features in Idiopathic Inflammatory Myopathies ( <i>Poster #85</i> )
<b>Ketevan Amirkhanashvili, MD</b>	Facial Diplegia in a Patient With Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome: A Rare Manifestation of Miller Fisher Syndrome ( <i>Poster #100</i> )
<b>Benjamin Becker, MD</b>	Nerve Conduction Studies of Sensory Nerves With Proven Vasculitic Neuropathy Often Show an Absent Electrical Response ( <i>Poster #98</i> )
<b>Miriam Bekhit, MD</b>	<ul style="list-style-type: none"> <li>Incidental Electrodiagnostic Findings of Left Riche-Cannieu and Right Marinacci Anastomosis: A Case Report (<i>Poster #76</i>)</li> <li>Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy Associated With Common Variable Immunodeficiency: A Case Report (<i>Poster #77</i>)</li> </ul>
<b>John Bireley, MD</b>	Diplopia in a 67-Year-Old Woman: A Case of Carotid Cavernous Fistula With Positive Acetylcholine Receptor Binding Antibody ( <i>Poster #73</i> )
<b>Meghan Branston, DO</b>	A Case of HMGCR Antibody Positive Necrotizing Myopathy After COVID-19 mRNA Vaccination ( <i>Poster #35</i> )
<b>Christopher Brewer, MD, PhD</b>	A Novel Intronic Alpha-Tropomyosin 3 Gene Mutation in a Patient With Nemaline Myopathy ( <i>Poster #50</i> )
<b>Luisa Castaño Herrera, MD</b>	Acute Motor Axonal Neuropathy With Lower Limb Involvement: Electrodiagnostic Study, Ultrasonography, and Magnetic Resonance Imaging ( <i>Poster #53</i> )
<b>Aaron Charnay, MD</b>	Peculiar Case of Traumatic Ulnar Nerve Injury Resulting in Denervation of Abductor Digiti Minimi While Sparing Other Hand Intrinsic, Giving Insight Into Interfascicular Anatomy of the Ulnar Nerve ( <i>Poster #99</i> )
<b>Katherine Clifford, MD</b>	Risk of Infection in Patients With Myasthenia Gravis With and Without Thymoma ( <i>Poster #36</i> )
<b>Tyler Crissinger, MD</b>	Lambert-Eaton Myasthenic Syndrome Presentation as Evaluation for Carpal Tunnel Syndrome ( <i>Poster #93</i> )
<b>Cole Denkensohn, MD</b>	Adalimumab-Induced Multifocal Motor Neuropathy - A Disabling but Reversible Phenomenon ( <i>Poster #34</i> )
<b>Joseph Ditrapani, MD, MPH</b>	Quantitative Ultrasound of the Rectus Femoris in Patients With Inclusion Body Myositis ( <i>Poster #78</i> )

<b>Akash Doshi, MD</b>	Track Chronic Inflammatory Demyelinating Polyneuropathy Progression Through Apple Watch (Poster #68)
<b>Vanessa Dwairi, MD</b>	Diagnosing X-Linked Myopathy With Excessive Autophagy After 30 Years: Genetic, Ultrasonographic, and Electrodiagnostic Findings (Poster #86)
<b>Colin Fry, MD</b>	Causes of Mononeuritis Multiplex: A Comprehensive, Structured Literature Review (Poster #39)
<b>Sukhraj Gill, MD</b>	<ul style="list-style-type: none"> <li>The Utility of Whole Exome Sequencing for Neuromuscular Conditions (Poster #64)</li> <li>How to Diagnose Amyloidosis Early? The Answer May Be in Your Hands (Poster #65)</li> </ul>
<b>Michelle Glantz, DO</b>	Conus Medullaris Syndromes Are a Common Mimic of Diverse Neuromuscular Diseases (Poster #79)
<b>Andre Granger, MD, MBA</b>	Descending Mononeuropathies: An Unusual Presentation of AL Amyloidosis (Poster #63)
<b>Julia Greenberg, MD</b>	Hiding in Plain Sight: A Case of Multifocal Acquired Demyelinating Sensory and Motor Neuropathy Masked by Multiple Concomitant Neuropathies (Poster #44)
<b>Morgan Heber, MD</b>	<ul style="list-style-type: none"> <li>A Case of Porphyric Neuropathy Misdiagnosed as Motor Neuron Disease (Poster #87)</li> <li>Is Repetitive Nerve Stimulation Testing Less Informative in Very Early-Stage Myasthenia Gravis? (Poster #88)</li> </ul>
<b>Alexis Kaiser, MD</b>	Successful Management of Painful Legs-Moving Toes Syndrome With Functional Electrical Stimulation (Poster #52)
<b>Nakul Katyal, MD</b>	<ul style="list-style-type: none"> <li>Clinical Experience With Ravulizumab for Treatment of Acetylcholine Receptor Positive Generalized Myasthenia Gravis (Poster #69)</li> <li>Plasmapheresis in Patients With Immune Checkpoint Inhibitors Related Myositis Without Myasthenia Gravis (Poster #70)</li> </ul>
<b>Nadia Khalil, MD</b>	Safety and Efficacy of Eculizumab Throughout Three Pregnancies in a Patient With Treatment Refractory Generalized Myasthenia Gravis (Poster #58)
<b>Javed Khanni, MD</b>	Relapsing Severe Immune-Mediated Demyelinating Polyneuropathy as a Presenting Feature of Systemic Lupus Erythematosus (Poster #75)
<b>Carlos Lara, MD</b>	Macroglossia as a Presenting Feature of the Adult Onset Pompe Disease (Poster #45)
<b>Mark Levine, MD, MA</b>	<ul style="list-style-type: none"> <li>Experience With Subcutaneous Immunoglobulin in Patients With Chronic Inflammatory Demyelinating Polyneuropathy and Other Acquired Demyelinating Neuropathies (Poster #95)</li> <li>A Rare, Atypical Case of Inclusion Body Myositis in a Patient With Dyspnea as the Chief and Predominant Complaint (Poster #96)</li> </ul>
<b>Trevor Logan, MD, PhD</b>	Ultrasonographic and Electrodiagnostic Evaluation of Focal Myokymia With Demyelinating Ulnar Neuropathy (Poster #40)
<b>Kyle Medley, DO</b>	Neurogenic Thoracic Outlet Syndrome Presenting Decades After Neonatal Brachial Plexus Palsy: Two Related Lesions? (Poster #83)
<b>Thomas Mehner, DO</b>	A Mistaken Diagnosis of Amyotrophic Lateral Sclerosis: A Case of Multiple Lumbar Nerve Root Schwannomas (Poster #46)
<b>James Meiling, DO</b>	<ul style="list-style-type: none"> <li>Bilateral Parsonage-Turner Syndrome With Flaccid Paralytic Biceps Brachii and Clinical Brachialis Sparing: A Case Report (Poster #80)</li> <li>Iatrogenic Brachial Plexopathy From an Interscalene Brachial Plexus Nerve Block: A Case Report (Poster #81)</li> </ul>
<b>Jenifer Moceri, DO</b>	Progressive Sensory Neuropathy as Initial Presentation of Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome (Poster #97)
<b>Jonathan Morena, DO</b>	Magnetic Resonance Neurography and Quantitative Muscle MRI of Parsonage-Turner Syndrome Involving the Long Thoracic Nerve (Poster #49)
<b>Chineze Nwebube, MD, MSc</b>	A Case of Fulminant Chronic Inflammatory Demyelinating Polyneuropathy (Poster #71)
<b>Shaida Omid, MD</b>	Onset of Radiation-Induced Brachial Plexopathy 30+ Years After Initial Exposure, A Case Report (Poster #60)
<b>Nathalia María Pérez Becerra, MD</b>	<ul style="list-style-type: none"> <li>Median and Radial Neuropathy Due to Brachial Artery Aneurysm: Case Report (Poster #47)</li> <li>Neuromuscular Ultrasound to Support Early Electrodiagnosis of Guillain-Barre Syndrome: A Case Report (Poster #48)</li> </ul>



<b>Saniya Pervin, MBBS</b>	Ultrasound Diagnosis of Carpal Tunnel Syndrome in Charcot-Marie-Tooth Type 2A <i>(Poster #72)</i>
<b>Laura Pinzón, MD</b>	<ul style="list-style-type: none"> <li>Tarsal Tunnel Syndrome Secondary to Post-Traumatic Cyst <i>(Poster #41)</i></li> <li>Neuromuscular Ultrasound as a Complementary Tool in Neurophysiologically Severe Polyneuropathy <i>(Poster #42)</i></li> </ul>
<b>Shubadra Priyadarshini, MD</b>	Mononeuritis Multiplex Secondary to Cryoglobulinemia-Mediated Vasculitis From Smoldering Myeloma: A Case Report <i>(Poster #59)</i>
<b>Taha Qarni, MD</b>	A Case of Bulbar-Predominant Axonal Polyneuropathy and Myopathy With an Inflammatory Component Associated With Vacuole, E1 Enzyme, X-Linked, Autoinflammatory, Somatic Syndrome <i>(Poster #43)</i>
<b>Benjamin Rardin, MD</b>	Acute Motor Axonal Neuropathy as a Complication of Graft Versus Host Disease <i>(Poster #90)</i>
<b>Nicolas Ruan dos Santos Cavalcante, MD</b>	Electrodiagnostic Characteristics of Sensory Ganglionopathies <i>(Poster #74)</i>
<b>Ashley Santilli, MD</b>	Contactin-1 Antibody Associated Inflammatory Polyradiculoneuropathy <i>(Poster #54)</i>
<b>Deborah Setter, MD, PhD</b>	Teaching Peripheral Neuroanatomy in a Digital Era: Designing and Assessing Online Modules <i>(Poster #66)</i>
<b>Roopa Sharma, MD</b>	Natural History of Conduction Slowing in Diabetic Distal Symmetric Polyneuropathy <i>(Poster #101)</i>
<b>Akhil Shivaprasad, MD</b>	Nodal and Paranodal Antibody Mediated Demyelinating Neuropathy <i>(Poster #51)</i>
<b>Madeline Singer, MD</b>	Multifocal Mononeuropathy Secondary to Inflammatory Pseudotumor of the Peripheral Nerve <i>(Poster #67)</i>
<b>Baljinder Singh, MD</b>	Novel A302T Variant in the Expanding Reticulon-2 Related Spectrum in Spastic Paraplegia 12 <i>(Poster #55)</i>
<b>Michael Skolka, MD</b>	The Utility of Electrodiagnostic Testing in Rhabdomyolysis <i>(Poster #1)</i>
<b>Sarah Smith, MD</b>	A Case of Primary Membranous Nephropathy in a Patient With Myasthenia Gravis <i>(Poster #94)</i>
<b>Hemani Ticku, MD</b>	<ul style="list-style-type: none"> <li>Neuromuscular Ultrasound Features of Sarcoid Tibial Mononeuropathy <i>(Poster #91)</i></li> <li>Nonlocalizable Ulnar Neuropathy Due to Ganglion Cyst - Role of Neuromuscular Ultrasound <i>(Poster #92)</i></li> </ul>
<b>Gautham Upadrasta, MD</b>	<ul style="list-style-type: none"> <li>Spinal Arteriovenous Fistula Initially Misdiagnosed as Chronic Inflammatory Demyelinating Polyneuropathy <i>(Poster #37)</i></li> <li>Sandpaper Arms: A Rare Neurological Presentation of Primary Sjogren Syndrome Initially Misdiagnosed as Guillain-Barre Syndrome <i>(Poster #38)</i></li> </ul>
<b>Sanem Pinar Uysal, MD</b>	Pitfalls in the Evaluation of Respiratory Failure in Myasthenia Gravis Patients: A Case Series <i>(Poster #61)</i>
<b>Amber Vocelle, DO, PhD</b>	Guyon Canal Neuropathy With Paresthesias in Digits 3-5: Electrodiagnostic Evidence of Berrettini Anastomosis May Explain Symptom Extension to Digit 3 <i>(Poster #82)</i>
<b>Thapat Wannarong, MD</b>	<ul style="list-style-type: none"> <li>Markedly Abnormal Lipid Accumulation in RRM2B-Related Progressive External Ophthalmoplegia: A Case Report <i>(Poster #102)</i></li> <li>Acquired Rippling Muscle Disease With Acetylcholine Receptor Antibodies <i>(Poster #103)</i></li> </ul>
<b>Josh Wilson, MD</b>	Longitudinal Management of Sialorrhea in Veterans With Amyotrophic Lateral Sclerosis Using Botulinum Toxin <i>(Poster #89)</i>
<b>Nathaniel Wooten, MD</b>	A Case of Ulnar Mononeuropathy From Hereditary Sensory and Autonomic Neuropathy Type IV Related Charcot Joint <i>(Poster #84)</i>

## ANF & IFCN Scholarship Recipients

---

The ANF and International Federation of Clinical Neurophysiology North American Chapter (IFCN NAC) scholarship programs provide opportunities for physicians who practice in economically developing countries to apply for funds to support their education through attendance at the AANEM Annual Meeting. Those who are attending virtually have had their registration covered by ANF and IFCN NAC. Those who were able to travel received a \$1,000 travel scholarship to help defray the cost of travel and meeting registration.

### American Neuromuscular Foundation

<b>Luisa Castaño Herrera, MD</b>	Acute Motor Axonal Neuropathy With Lower Limb Involvement: Electrodiagnostic Study, Ultrasonography, and Magnetic Resonance Imaging (Poster #53)
<b>Nicolas Ruan dos Santos Cavalcante, MD</b>	Electrodiagnostic Characteristics of Sensory Ganglionopathies (Poster #74)
<b>Otto Hernandez Fustes, MD, MSc, PhD</b>	<ul style="list-style-type: none"><li>• Pain-Related Evoked Potentials: Normative Data (Poster #214)</li><li>• Analysis of Indications for Electroneuromyographic Studies (Poster #215)</li><li>• 100th Anniversary of the Cutaneous Silent Period Test: Current Relevance in Clinical Neurophysiology (Poster #230)</li><li>• “Axonal” Landry-Guillain-Barre-Strohl Syndrome in the Latin American Book of 1976 (Poster #231)</li></ul>
<b>Nathalia María Pérez Becerra, MD</b>	<ul style="list-style-type: none"><li>• Median and Radial Neuropathy Due to Brachial Artery Aneurysm: Case Report (Poster #47)</li><li>• Neuromuscular Ultrasound to Support Early Electrodiagnosis of Guillain-Barre Syndrome: A Case Report (Poster #48)</li></ul>
<b>Eman A. Tawfik, MD</b>	<ul style="list-style-type: none"><li>• Non-Neuromuscular Pathologies in Patients Primarily Referred for Neuromuscular Ultrasound: Report of Two Cases (Poster #224)</li></ul>

### International Federation of Clinical Neurophysiology North American Chapter

<b>Mrinal Acharya, MBBS, MD, DM</b>	Hirayama Disease: A Electrophysio-Radiological Documentary (Poster #170)
<b>Sandra Milena Barrera Castro, MD</b>	Carpal Tunnel Syndrome Related to Lymphedema in Women With Breast Cancer (Poster #118)
<b>Andrea Bonfante, MD</b>	Bickerstaff Brainstem Encephalitis in a Young Patient: A Case Report in Bogota, Colombia (Poster #216)
<b>Mengjie Chen, MD</b>	<ul style="list-style-type: none"><li>• Motor Unit Number Index in Idiopathic Facial Palsy (Poster #116)</li><li>• Case Report: Acute Onset of Respiratory Distress Caused by Idiopathic Brachial Plexopathy (Poster #117)</li></ul>
<b>Hala Elhabashy, MD</b>	Transcranial Direct Current Stimulation in Multiple Sclerosis: Exploring Novel Routes (Poster #8)
<b>Abeer El-Zohiery, MD</b>	Fibromyalgia Syndrome: Is There a Correlation Between Electrodiagnostic Findings and Muscle Histopathology? (Poster #120)
<b>Xinhong Feng, MD</b>	Clinical, Neurophysiological, and Ultrasonic Changes in a Case of Peripheral Nerve Damage in Leprosy (Poster #113)
<b>Naglaa Gadallah, MD</b>	Objective Prognostic Parameters for Management of Spasticity: Clinical, Electrodiagnostic, and Surgical Study (Poster #7)
<b>Joel Gutiérrez, MD, PhD</b>	Nerve Conduction Studies in Patients With Familial Dysautonomia (Poster #212)
<b>Oksana Haiko, MD, PhD, ScD</b>	The Role of Ultrasound in Diagnosis of Nerve Injury After Gunshot Wounds and Blast Injuries (Poster #3)
<b>Wilmer Santiago Herrera Malpica, MD</b>	Bethlem Myopathy Clinical View With Ultrasonography and Electrodiagnosis: A Case Report (Poster #187)
<b>Xiao Huan, MD</b>	Thymoma-Associated Myasthenic Crisis: A Multicenter Retrospective Cohort Study (Poster #186)
<b>Maha Ibrahim, MD</b>	Role of Tgf-1 $\beta$ Gene Polymorphisms in the Pathogenesis of Carpal Tunnel Syndrome in Egyptian Patients (Poster #164)
<b>Daniel Manrique Hernandez, MD</b>	Late-Onset P.Val142Ile Transthyretin Amyloidosis Mixed Phenotype in an Elderly Person in a Non-Endemic Area: A Case Report In Colombia (Poster #232)

<b>Josué Moreno, MD</b>	<ul style="list-style-type: none"> <li>• Dissociation Between Creatine Kinase Levels and Myopathic Symptoms in Immune-Mediated Necrotizing Myopathy: A Case Report (Poster #121)</li> <li>• Encephalomyelitis Longitudinally Extensive With Polyradiculitis as a Debut of Neuropsychiatric Lupus: A Case Report (Poster #122)</li> </ul>
<b>Jose Pedro Soares Baima, MD</b>	Mononeuritis Multiplex: A Case Series (Poster #126)
<b>Rachel Pérez-Lalana, MD</b>	Mechanically Induced Somatosensory Evoked Potentials: Genuine Electrophysiological Responses or Movement Artifacts? (Poster #162)
<b>Laura Pinzón, MD</b>	<ul style="list-style-type: none"> <li>• Tarsal Tunnel Syndrome Secondary to Post-Traumatic Cyst (Poster #41)</li> <li>• Neuromuscular Ultrasound as a Complementary Tool in Neurophysiologically Severe Polyneuropathy (Poster #42)</li> </ul>
<b>Andersson Rozo, MD</b>	Reference Values of Electromyography Studies of the Masseter and Temporal Muscles (Poster #195)
<b>Manqiqige Su, MD</b>	Nomogram for Prediction of Pregnancy-Related Clinical Worsening in Myasthenia Gravis Patients (Poster #182)
<b>Hongfei Tai, MD</b>	Peripheral Nerve Involvement in Neuronal Intranuclear Inclusion Disease: Prospective Clinical and Neurophysiological Studies (Poster #218)
<b>Ailin Stephanie Ventura, MD</b>	Carpal Tunnel Syndrome in Amyloidosis: An Early Marker of the Disease (Poster #140)
<b>Yan Wang, MD</b>	Early Diagnostic and Prognostic Value of Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis (Poster #221)

# Poster Presentations List

Session I: Thursday, 6-6:30 pm | Session II: Friday, 9:30-10 am | Session III: Friday, 3:30-4 pm

Poster Number	Abstract Title	Presenting Author	Presentation Sessions
1	THE UTILITY OF ELECTRODIAGNOSTIC TESTING IN RHABDOMYOLYSIS	Michael Skolka, MD	I & II
2	LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY 4 YEARS POST-TREATMENT WITH DELANDISTROGENE MOXEPARVOVEC IN A PHASE 1/2A STUDY	Jerry Mendell, MD	I & III
3	THE ROLE OF ULTRASOUND IN DIAGNOSIS OF NERVE INJURY AFTER GUNSHOT WOUNDS AND BLAST INJURIES	Oksana Haiko, MD, PhD, ScD	I & II
4	A SURVEY OF NERVE CONDUCTION TECHNOLOGISTS' ROLE IN EMG LABS	Stephanie Harvey, CNCT	I & III
5	PATIENT REPORTED IMPACT OF SYMPTOMS IN SPINAL BULBAR MUSCULAR ATROPHY	Abdullah Al Qahtani, MD, MPH	I & II
6	ASSESSING REHAB NEEDS IN CHILDREN WITH SPINAL MUSCULAR ATROPHY STATUS POST ONASEMNOGENE ABEPARVOVEC-XIOI	Julia Shah, MD	I & III
7	OBJECTIVE PROGNOSTIC PARAMETERS FOR MANAGEMENT OF SPASTICITY: CLINICAL, ELECTRODIAGNOSTIC, AND SURGICAL STUDY	Naglaa Gadallah, MD	I & II
8	TRANSCRANIAL DIRECT CURRENT STIMULATION IN MULTIPLE SCLEROSIS: EXPLORING NOVEL ROUTES	Hala Elhabashy, MD	I & III
9	VIRTUAL EXERCISE GROUP PROGRAMS FOR REHABILITATION OF VETERANS WITH AMYOTROPHIC LATERAL SCLEROSIS	Hallie Walsh, BA	I & II
10	EVALUATION OF NEUROMUSCULAR PROVIDER PERCEPTIONS AND OFFICE SETUP FOR EVALUATING PATIENTS WITH DISABILITIES	Adeel Zubair, MD	I & III
11	IMPACT OF EDARAVONE ON THE AMYOTROPHIC LATERAL SCLEROSIS COURSE AT TTUHSC EL PASO CLINIC: A PROSPECTIVE COHORT STUDY	Ryan Floresca, BS	I & II
12	CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IS ASSOCIATED WITH DECREASED EXECUTIVE FUNCTIONING IN CANCER SURVIVORS	Brendan McNeish, MD	I & III
13	ARE NEUROMUSCULAR DISEASES ASSOCIATED WITH A GREATER LEVEL OF NEURO-PSYCHIATRIC CONDITIONS?	Mohsen Ahmed, BS	I & III
15	AN ULTRA-RARE GENETIC CAUSE OF GLOBAL DEVELOPMENTAL DELAY AND SEVERE HYPOTONIA	Tyler Cook, MS	I & II
16	A CASE OF SLOWLY PROGRESSIVE ASCENDING WEAKNESS AFTER COVID-19 VACCINE	Jonathan Espinosa, BSA	I & III
17	CLINICAL AND DIAGNOSTIC FEATURES OF SMALL FIBER NEUROPATHY WITH FIBROBLAST GROWTH FACTOR RECEPTOR 3 ANTIBODIES	Margarita Fedorova, BA	I & II
18	URINE SECRETORY PHOSPHOLIPASE A2 IN DEMYELINATING DIABETIC DISTAL SYMMETRIC POLYNEUROPATHY	Kazim Jaffry, BA	I & II
19	COMPARING MORTALITY AND MORBIDITY IN STANDARD TREATMENT PROTOCOLS FOR GUILLAIN-BARRE SYNDROME	Kazim Jaffry, BA	I & II
20	TEMPORAL CHANGES IN TRENDS AND OUTCOMES FOR MULTIFOCAL MOTOR NEUROPATHY	Kazim Jaffry, BA	I & II
21	IDENTIFICATION OF TRENDS AND CLINICAL OUTCOMES IN PEDIATRIC BOTULISM	Kazim Jaffry, BA	I & II
22	THE "ROGUE WAVE SIGN" AS AN INDICATOR OF AN ENTRAPMENT MONONEUROPATHY: A CASE REPORT	Angela Ballesteros, BS	I & III
23	WHAT IS THE MOST EFFECTIVE USE OF BISPHOSPHONATES TO OPTIMISE BONE HEALTH IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY?	Nikhita Valipe	I & III
24	WHAT A WASTE! (OF THENAR MUSCLE): A SERVICE IMPROVEMENT AUDIT	Lisa McReynolds, MBBCH	I & II
25	PERFORMANCE OF ACADEMIC AND NON-ACADEMIC CENTERS IN TREATMENT OF GUILLAIN-BARRE SYNDROME	Mohsen Ahmed, BS	I & III
26	OUTCOMES FOR PATIENTS WITH NEUROMUSCULAR DISEASE FOLLOWING INVASIVE NEUROLOGICAL PROCEDURES	Mohsen Ahmed, BS	I & III
28	ULTRASOUND AS A DIAGNOSTIC MODALITY FOR WRIST PAIN IN A NONVERBAL PATIENT WITH AUTISM SPECTRUM DISORDER	Nicole Zougheib, MBA	I & III
29	CLINICAL DISPARITIES BETWEEN CAUCASIANS AND AFRICAN AMERICANS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A	Olivia Pakula, BA	I & II
30	JUVENILE MYASTHENIA GRAVIS IN NORTH TEXAS: CLINICAL FEATURES, TREATMENT RESPONSE, AND OUTCOMES	Marilyn Lu, BA	I & III
31	DEEP BRAIN STIMULATION FOR THE MANAGEMENT OF AIFM1-RELATED DISABLING TREMOR: A CASE SERIES	Jude Tunyi, BS	I & II
32	THE PROVIDER'S PERSPECTIVE ON NEWER THERAPEUTICS FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS: A CROSS-SECTIONAL SURVEY	Huang He Ding, BS	I & III
33	REGIONAL DISPARITIES IN TREATMENT OUTCOMES FOR PATIENTS WITH MYASTHENIA GRAVIS EXACERBATION	Afaaq Ahmed, BS	I & II
34	ADALIMUMAB-INDUCED MULTIFOCAL MOTOR NEUROPATHY - A DISABLING BUT REVERSIBLE PHENOMENON	Cole Denkensohn, MD	I & III
35	A CASE OF HMGR ANTIBODY POSITIVE NECROTIZING MYOPATHY AFTER COVID-19 MRNA VACCINATION	Meghan Branstion, DO	I & II
36	RISK OF INFECTION IN PATIENTS WITH MYASTHENIA GRAVIS WITH AND WITHOUT THYMOMA	Katherine Clifford, MD	I & III
37	SPINAL ARTERIOVENOUS FISTULA INITIALLY MISDIAGNOSED AS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	Gautham Upadrasta, MD	I & II
38	SANDPAPER ARMS: A RARE NEUROLOGICAL PRESENTATION OF PRIMARY SJOGREN SYNDROME INITIALLY MISDIAGNOSED AS GUILLAIN-BARRE SYNDROME	Gautham Upadrasta, MD	I & II
39	CAUSES OF MONONEURITIS MULTIPLEX: A COMPREHENSIVE, STRUCTURED LITERATURE REVIEW	Colin Fry, MD	I & III
40	ULTRASONOGRAPHIC AND ELECTRODIAGNOSTIC EVALUATION OF FOCAL MYOKYMIA WITH DEMYELINATING ULNAR NEUROPATHY	Trevor Logan, MD, PhD	I & II
41	TARSAL TUNNEL SYNDROME SECONDARY TO POST-TRAUMATIC CYST	Laura Pinzón, MD	I & III
42	NEUROMUSCULAR ULTRASOUND AS A COMPLEMENTARY TOOL IN NEUROPHYSIOLOGICALLY SEVERE POLYNEUROPATHY	Laura Pinzón, MD	I & III

43	A CASE OF BULBAR-PREDOMINANT AXONAL POLYNEUROPATHY AND MYOPATHY WITH AN INFLAMMATORY COMPONENT ASSOCIATED WITH VACUOLE, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME	Taha Qarni, MD	I & II
44	HIDING IN PLAIN SIGHT: A CASE OF MULTIFOCAL ACQUIRED DEMYELINATING SENSORY AND MOTOR NEUROPATHY MASKED BY MULTIPLE CONCOMITANT NEUROPATHIES	Julia Greenberg, MD	I & III
45	MACROGLOSSIA AS A PRESENTING FEATURE OF THE ADULT ONSET POMPE DISEASE	Carlos Lara, MD	I & II
46	A MISTAKEN DIAGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS: A CASE OF MULTIPLE LUMBAR NERVE ROOT SCHWANNOMAS	Thomas Mehner, DO	I & III
47	MEDIAN AND RADIAL NEUROPATHY DUE TO BRACHIAL ARTERY ANEURYSM: CASE REPORT	Nathalia María Pérez Becerra, MD	I & II
48	NEUROMUSCULAR ULTRASOUND TO SUPPORT EARLY ELECTRODIAGNOSIS OF GUILLAIN-BARRE SYNDROME: A CASE REPORT	Nathalia María Pérez Becerra, MD	I & II
49	MAGNETIC RESONANCE NEUROGRAPHY AND QUANTITATIVE MUSCLE MRI OF PARSONAGE-TURNER SYNDROME INVOLVING THE LONG THORACIC NERVE	Jonathan Morena, DO	I & III
50	A NOVEL INTRONIC ALPHA-TROPOMYOSIN 3 GENE MUTATION IN A PATIENT WITH NEMALINE MYOPATHY	Christopher Brewer, MD, PhD	I & II
51	NODAL AND PARANODAL ANTIBODY MEDIATED DEMYELINATING NEUROPATHY	Akhil Shivaprasad, MD	I & III
52	SUCCESSFUL MANAGEMENT OF PAINFUL LEGS-MOVING TOES SYNDROME WITH FUNCTIONAL ELECTRICAL STIMULATION	Alexis Kaiser, MD	I & II
53	ACUTE MOTOR AXONAL NEUROPATHY WITH LOWER LIMB INVOLVEMENT: ELECTRODIAGNOSTIC STUDY, ULTRASONOGRAPHY, AND MAGNETIC RESONANCE IMAGING	Luisa Castaño Herrera, MD	I & III
54	CONTACTIN-1 ANTIBODY ASSOCIATED INFLAMMATORY POLYRADICULONEUROPATHY	Ashley Santilli, MD	I & II
55	NOVEL A302T VARIANT IN THE EXPANDING RETICULON-2 RELATED SPECTRUM IN SPASTIC PARAPLEGIA 12	Baljinder Singh, MD	I & III
56	A CASE OF POST-INFECTIOUS HERPES SIMPLEX VIRUS TYPE 1-RELATED BIBRACHIAL PAN-PLEXOPATHY	Adenike Adewuyi, MD, PhD	I & III
57	OBINUTUZUMAB FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY	Adenike Adewuyi, MD, PhD	I & III
58	SAFETY AND EFFICACY OF ECULIZUMAB THROUGHOUT THREE PREGNANCIES IN A PATIENT WITH TREATMENT REFRACTORY GENERALIZED MYASTHENIA GRAVIS	Nadia Khalil, MD	I & II
59	MONONEURITIS MULTIPLEX SECONDARY TO CRYOGLOBULINEMIA-MEDIATED VASCULITIS FROM SMOLDERING MYELOMA: A CASE REPORT	Shubadra Priyadarshini, MD	I & III
60	ONSET OF RADIATION-INDUCED BRACHIAL PLEXOPATHY 30+ YEARS AFTER INITIAL EXPOSURE, A CASE REPORT	Shaida Omid, MD	I & II
61	PITFALLS IN THE EVALUATION OF RESPIRATORY FAILURE IN MYASTHENIA GRAVIS PATIENTS: A CASE SERIES	Sanem Pinar Uysal, MD	I & III
62	A TONGUE TWISTER: TONGUE WEAKNESS DUE TO PARANEOPLASTIC SYNDROME IN MULTIPLE MYELOMA	Ian Ackers, DO, PhD	I & II
63	DESCENDING MONONEUROPATHIES: AN UNUSUAL PRESENTATION OF AL AMYLOIDOSIS	Andre Granger, MD, MBA	I & III
64	THE UTILITY OF WHOLE EXOME SEQUENCING FOR NEUROMUSCULAR CONDITIONS	Sukhraj Gill, MD	I & II
65	HOW TO DIAGNOSE AMYLOIDOSIS EARLY? THE ANSWER MAY BE IN YOUR HANDS	Sukhraj Gill, MD	I & II
66	TEACHING PERIPHERAL NEUROANATOMY IN A DIGITAL ERA: DESIGNING AND ASSESSING ONLINE MODULES	Deborah Setter, MD, PhD	I & III
67	MULTIFOCAL MONONEUROPATHY SECONDARY TO INFLAMMATORY PSEUDOTUMOR OF THE PERIPHERAL NERVE	Madeline Singer, MD	I & II
68	TRACK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PROGRESSION THROUGH APPLE WATCH	Akash Doshi, MD	I & III
69	CLINICAL EXPERIENCE WITH RAVULIZUMAB FOR TREATMENT OF ACETYLCHOLINE RECEPTOR POSITIVE GENERALIZED MYASTHENIA GRAVIS	Nakul Katyal, MD	I & III
70	PLASMAPHERESIS IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITORS RELATED MYOSITIS WITHOUT MYASTHENIA GRAVIS	Nakul Katyal, MD	I & III
71	A CASE OF FULMINANT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	Chineze Nwebube, MD, MSc	I & II
72	ULTRASOUND DIAGNOSIS OF CARPAL TUNNEL SYNDROME IN CHARCOT-MARIE-TOOTH TYPE 2A	Saniya Pervin, MBBS	I & III
73	DIPLOPIA IN A 67-YEAR-OLD WOMAN: A CASE OF CAROTID CAVERNOUS FISTULA WITH POSITIVE ACETYLCHOLINE RECEPTOR BINDING ANTIBODY	John Bireley, MD	I & II
74	ELECTRODIAGNOSTIC CHARACTERISTICS OF SENSORY GANGLIONOPATHIES	Nicolas Ruan dos Santos Cavalcante, MD	I & III
75	RELAPSING SEVERE IMMUNE-MEDIATED DEMYELINATING POLYNEUROPATHY AS A PRESENTING FEATURE OF SYSTEMIC LUPUS ERYTHEMATOSUS	Javed Khanni, MD	I & II
76	INCIDENTAL ELECTRODIAGNOSTIC FINDINGS OF LEFT RICHE-CANNIEU AND RIGHT MARINACCI ANASTOMOSIS: A CASE REPORT	Miriam Bekhit, MD	I & III
77	ACUTE-ONSET CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY ASSOCIATED WITH COMMON VARIABLE IMMUNODEFICIENCY: A CASE REPORT	Miriam Bekhit, MD	I & III
78	QUANTITATIVE ULTRASOUND OF THE RECTUS FEMORIS IN PATIENTS WITH INCLUSION BODY MYOSITIS	Joseph Ditrapani, MD, MPH	I & II
79	CONUS MEDULLARIS SYNDROMES ARE A COMMON MIMIC OF DIVERSE NEUROMUSCULAR DISEASES	Michelle Glantz, DO	I & III
80	BILATERAL PARSONAGE-TURNER SYNDROME WITH FLACCID PARALYTIC BICEPS BRACHII AND CLINICAL BRACHIALIS SPARING: A CASE REPORT	James Meiling, DO	I & II
81	IATROGENIC BRACHIAL PLEXOPATHY FROM AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK: A CASE REPORT	James Meiling, DO	I & II
82	GUYON CANAL NEUROPATHY WITH PARESTHESIAS IN DIGITS 3-5: ELECTRODIAGNOSTIC EVIDENCE OF BERRETTINI ANASTOMOSIS MAY EXPLAIN SYMPTOM EXTENSION TO DIGIT 3	Amber Vocelle, DO, PhD	I & III
83	NEUROGENIC THORACIC OUTLET SYNDROME PRESENTING DECADES AFTER NEONATAL BRACHIAL PLEXUS PALSY: TWO RELATED LESIONS?	Kyle Medley, DO	I & II



84	A CASE OF ULNAR MONONEUROPATHY FROM HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE IV RELATED CHARCOT JOINT	Nathaniel Wooten, MD	I & II
85	ATYPICAL PATHOLOGICAL FEATURES IN IDIOPATHIC INFLAMMATORY MYOPATHIES	Hassan Alhussein, MD	I & III
86	DIAGNOSING X-LINKED MYOPATHY WITH EXCESSIVE AUTOPHAGY AFTER 30 YEARS: GENETIC, ULTRASONOGRAPHIC, AND ELECTRODIAGNOSTIC FINDINGS	Vanessa Dwairi, MD	I & II
87	A CASE OF PORPHYRIC NEUROPATHY MISDIAGNOSED AS MOTOR NEURON DISEASE	Morgan Heber, MD	I & III
88	IS REPETITIVE NERVE STIMULATION TESTING LESS INFORMATIVE IN VERY EARLY-STAGE MYASTHENIA GRAVIS?	Morgan Heber, MD	I & III
89	LONGITUDINAL MANAGEMENT OF SIALORRHEA IN VETERANS WITH AMYOTROPHIC LATERAL SCLEROSIS USING BOTULINUM TOXIN	Josh Wilson, MD	I & II
90	ACUTE MOTOR AXONAL NEUROPATHY AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE	Benjamin Rardin, MD	I & III
91	NEUROMUSCULAR ULTRASOUND FEATURES OF SARCOID TIBIAL MONONEUROPATHY	Hemani Ticku, MD	I & II
92	NONLOCALIZABLE ULNAR NEUROPATHY DUE TO GANGLION CYST - ROLE OF NEUROMUSCULAR ULTRASOUND	Hemani Ticku, MD	I & II
93	LAMBERT-EATON MYASTHENIC SYNDROME PRESENTATION AS EVALUATION FOR CARPAL TUNNEL SYNDROME	Tyler Crissinger, MD	I & III
94	A CASE OF PRIMARY MEMBRANOUS NEPHROPATHY IN A PATIENT WITH MYASTHENIA GRAVIS	Sarah Smith, MD	I & III
95	EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY AND OTHER ACQUIRED DEMYELINATING NEUROPATHIES	Mark Levine, MD, MA	I & III
96	A RARE, ATYPICAL CASE OF INCLUSION BODY MYOSITIS IN A PATIENT WITH DYSPNEA AS THE CHIEF AND PREDOMINANT COMPLAINT	Mark Levine, MD, MA	I & III
97	PROGRESSIVE SENSORY NEURONOPATHY AS INITIAL PRESENTATION OF CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME	Jenifer Mocerri, DO	I & II
98	NERVE CONDUCTION STUDIES OF SENSORY NERVES WITH PROVEN VASCULITIC NEUROPATHY OFTEN SHOW AN ABSENT ELECTRICAL RESPONSE	Benjamin Becker, MD	I & III
99	PECULIAR CASE OF TRAUMATIC ULNAR NERVE INJURY RESULTING IN DENERVATION OF ABDUCTOR DIGITI MINIMI WHILE SPARING OTHER HAND INTRINSICS, GIVING INSIGHT INTO INTERFASCICULAR ANATOMY OF THE ULNAR NERVE	Aaron Charnay, MD	I & II
100	FACIAL DIPLEGIA IN A PATIENT WITH HEMOLYSIS, ELEVATED LIVER ENZYMES, AND LOW PLATELETS SYNDROME: A RARE MANIFESTATION OF MILLER FISHER SYNDROME	Ketevan Amirkhanashvili, MD	I & III
101	NATURAL HISTORY OF CONDUCTION SLOWING IN DIABETIC DISTAL SYMMETRIC POLYNEUROPATHY	Roopa Sharma, MD	I & II
102	MARKEDLY ABNORMAL LIPID ACCUMULATION IN RRM2B-RELATED PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA: A CASE REPORT	Thapat Wannarong, MD	I & II
103	ACQUIRED RIPPLING MUSCLE DISEASE WITH ACETYLCHOLINE RECEPTOR ANTIBODIES	Thapat Wannarong, MD	I & II
104	ACUTE FLACCID PARALYSIS AMONG ADULT ADMISSIONS TO THE UNIVERSITY TEACHING HOSPITAL IN LUSAKA, ZAMBIA: ETIOLOGIES AND CLINICAL CHARACTERISTICS	Michelle Kvalsund, DO	I & III
105	PATIENT-REPORTED SEVERITY OF PAIN INTERFERENCE IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A: FINDINGS FROM A DIGITAL REAL-WORLD STUDY	Youcef Boutalbi, MD	I & II
106	PATIENT-REPORTED SYMPTOM SEVERITY OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A: FINDINGS FROM A DIGITAL REAL-WORLD STUDY	Youcef Boutalbi, MD	I & II
107	VIDEO-BASED GAIT ANALYSIS OF SPASTIC HEMIPARETIC GAIT	Ronald Cotton, MD, PhD	I & III
108	RECURRENCE OF ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY IN FORTY MONTHS IN ONE ADULT PATIENT WITH EXCELLENT RECOVERY	Ali Al-Samak, MD	I & II
109	IMPROVING MILD CARPAL TUNNEL SYNDROME DETECTION WITH AN ADDITIONAL (MEDIAN - ULNAR) LATENCY COMPARISON	Elliot Bodofsky, MD	I & III
110	LONG-TERM HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH NEWLY DIAGNOSED MYASTHENIA GRAVIS: A SWEDISH NATIONWIDE POPULATION-BASED STUDY	Alberto Batista, PharmD	I & II
111	A COMPUTER-DRIVEN MODEL TO IDENTIFY CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: A PLANNED ANALYSIS IN THE PHASE 2B TRIAL OF THE FCN INHIBITOR, BATOCLIMAB	Todd Levine, MD	I & III
112	THE SYNNUCLEIN-ONE STUDY: DETECTION OF CUTANEOUS PHOSPHORYLATED ALPHA-SYNUCLEIN FOR THE DIAGNOSIS OF PURE AUTONOMIC FAILURE	Todd Levine, MD	I & III
113	CLINICAL, NEUROPHYSIOLOGICAL, AND ULTRASONIC CHANGES IN A CASE OF PERIPHERAL NERVE DAMAGE IN LEPROSY	Xinhong Feng, MD	I & II
114	IMMUNOGLOBULIN G REDUCTION EXPLAINS A LARGE PROPORTION OF CLINICAL EFFICACY IN GENERALIZED MYASTHENIA GRAVIS – A MODEL-BASED META-ANALYSIS OF FCN INHIBITORS	Mehrdad Javidi, PhD	I & III
115	EVALUATION OF COMPLEMENT BIOMARKERS AFTER TREATMENT WITH NIPOCALIMAB IN GENERALIZED MYASTHENIA GRAVIS	Nancy Zhang, MD	I & II
116	MOTOR UNIT NUMBER INDEX IN IDIOPATHIC FACIAL PALSY	Mengjie Chen, MM	I & II
117	CASE REPORT: ACUTE ONSET OF RESPIRATORY DISTRESS CAUSED BY IDIOPATHIC BRACHIAL PLEXOPATHY	Mengjie Chen, MM	I & II
118	CARPAL TUNNEL SYNDROME RELATED TO LYMPHEDEMA IN WOMEN WITH BREAST CANCER	Sandra Milena Barrera Castro, MD	I & III
119	UNILATERAL SPINAL ACCESSORY NERVE INJURY ASSOCIATED WITH PLEXOPATHY SECONDARY TO RESECTION OF PAPILLARY THYROID CARCINOMA	Raul Galvis, MD	I & II
120	FIBROMYALGIA SYNDROME: IS THERE A CORRELATION BETWEEN ELECTRODIAGNOSTIC FINDINGS AND MUSCLE HISTOPATHOLOGY?	Abeer El-Zohiery, MD	I & III
121	DISSOCIATION BETWEEN CREATINE KINASE LEVELS AND MYOPATHIC SYMPTOMS IN IMMUNE-MEDIATED NECROTIZING MYOPATHY: A CASE REPORT	Josue Moreno, MD	I & III
122	ENCEPHALOMYELITIS LONGITUDINALLY EXTENSIVE WITH POLYRADICULITIS AS A DEBUT OF NEUROPSYCHIATRIC LUPUS: A CASE REPORT	Josue Moreno, MD	I & III
123	THE STUDY OF MUSCLE ELASTICITY USING SHEAR WAVE ELASTOGRAPHY	Kyle Tse, MD	I & II

124	PROXIMAL CONDUCTION BLOCK MASQUERADING AS AXONOTMETIC TRAUMATIC BRACHIAL PLEXOPATHY	Niki Grzywnowicz, MSc	I & II
125	IATROGENIC RADIAL NERVE PALSY FROM INTRAMUSCULAR INJECTION	Niki Grzywnowicz, MSc	I & II
126	MONONEURITIS MULTIPLEX: A CASE SERIES	Jose Pedro Soares Baima, MD	I & III
127	CHARACTERISTICS OF AUTOIMMUNE NODO-PARANODOPATHIES IN CHINA	Hai Chen, MD	I & II
128	A RARE CASE OF HERPES ZOSTER LUMBOSACRAL PLEXOPATHY CAUSING LIMB PARESIS, PELVIC INSTABILITY, AND VESICULAR RASH	Derrick Fox, MD	I & III
129	OUTCOME OF MYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	Rasha Moussallem, MD	I & III
130	MILLS SYNDROME VARIANT	Rasha Moussallem, MD	I & III
131	INDIVIDUALIZING THERAPY FOR GENERALIZED MYASTHENIA GRAVIS: CAN CONTINUING MEDICAL EDUCATION HELP GUIDE TREATING CLINICIANS?	Carole Drexel, PhD	I & II
132	PEDIATRIC HMGCR-ASSOCIATED NECROTIZING MYOPATHY IN THE SETTING OF AN RYR1 VARIANT	Cassie Turnage, MD	I & III
133	SHORT-TERM PROGNOSTIC VALUE OF BLINK REFLEX AND FACIAL NERVE CONDUCTION STUDY ON BELL PALSY	Bum Chun Suh, MD	I & II
134	IMMUNOGLOBULIN-G4 RELATED HYPERTROPHIC PACHYMENINGITIS PRESENTING AS MULTIPLE LOWER CRANIAL NERVE PALSIES	Bum Chun Suh, MD	I & II
135	IMPROVING SEROLOGICAL DIAGNOSIS OF MYASTHENIA GRAVIS BY A COMPREHENSIVE REFLEX TESTING ALGORITHM: A REAL WORLD EXPERIENCE WITH MORE THAN TWELVE THOUSAND PATIENT SAMPLES	Hans Frykman, MD, PhD	I & III
136	FORTY YEARS OF IMPROVING DIAGNOSTIC TESTING FOR MYASTHENIA GRAVIS	Hans Frykman, MD, PhD	I & III
137	CONTRASTING CLINICAL AND LABORATORY FEATURES ARE HELPFUL IN DIAGNOSING MCARDLE DISEASE	Grace Li, BA	I & II
138	DIAGNOSIS INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES	A. Gordon Smith, MD	I & III
139	TREATMENT-RELATED INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES	A. Gordon Smith, MD	I & III
140	CARPAL TUNNEL SYNDROME IN AMYLOIDOSIS: AN EARLY MARKER OF THE DISEASE	Ailin Stephanie Ventura, MD	I & II
141	ANTIGEN-SPECIFIC IMMUNE THERAPY (CNP-106) FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS: RATIONALE AND DESIGN OF FIRST IN-HUMAN RANDOMIZED CONTROLLED TRIAL	Michael Boyne, PhD	I & III
142	THE EFFECTS OF EARLY INITIATION OF IVIG IN THE TREATMENT OF ANTI-HMGCR IMMUNE-MEDIATED NECROTIZING MYOPATHY	Kyle Sharf, DO	I & II
143	EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: RESULTS FROM THE ADHERE TRIAL	Richard Lewis, MD	I & II
144	PHASE 2 PROOF-OF-CONCEPT TRIAL EVALUATING SAR445088, A MONOCLONAL ANTIBODY TARGETING COMPLEMENT C1S, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	Richard A. Lewis, MD	I & II
145	MULTIFOCAL MOTOR NEUROPATHY WITH CONCURRENT SMALL FIBER AUTONOMIC NEUROPATHY	Arindra Jayasekara, MD	I & III
146	CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH MULTIFOCAL MOTOR NEUROPATHY AND MIMIC DISORDERS: RETROSPECTIVE COHORT STUDY OF A UNITED STATES CLAIMS DATABASE	Chafic Karam, MD	I & II
147	REDUCED IMMUNOGLOBULIN G AND ANTI-ACETYLCHOLINE RECEPTOR ANTIBODIES EXPLAIN NIPOCALIMAB EFFECT ON IMPROVED MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING SCORE IN GENERALIZED MYASTHENIA GRAVIS PATIENTS	Sindhu Ramchandren, MD	I & III
148	QIGONG FOR PAINFUL DIABETIC POLYNEUROPATHY	Jinny Tavee, MD	I & II
149	AMYLOID MYOPATHY WITH PATHOLOGICAL RESEMBLANCE TO DERMATOMYOSITIS	Reena Bastin, MD	I & III
150	NERVE ALPHA-SYNUCLEIN IN SMALL-FIBER NEUROPATHY	Matthew Schelke, MD	I & II
151	LONG-TERM EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM ANALYSIS OF THE ADAPT-SC+ STUDY	James F. Howard Jr., MD	I & III
152	LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CONCLUDING ANALYSES FROM THE ADAPT+ STUDY	James F. Howard Jr., MD	I & III
153	TREATMENT OUTCOMES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS TREATED WITH ECUZUMAB AND RAVULIZUMAB: A CASE SERIES	Andrew Gordon, MD	I & II
154	PHARYNGEAL-CERVICAL-BRACHIAL VARIANT OF GUILLAIN-BARRE SYNDROME IN A MIDDLE-AGED PATIENT: A CASE REPORT IN CHÍA, CUNDINAMARCA	Claudia Peña, MD	I & III
155	PHASE 3B EXTENSION STUDY EVALUATING SUPERIORITY OF DAILY VS APPROVED ON/OFF ORAL EDARAVONE DOSING IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS	Stephen Apple, MD	I & II
156	DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING MAY IDENTIFY PATIENTS WITH INFLAMMATORY NEUROPATHIES	Edrich Rodrigues, MBChB	I & III
157	MAGNETIC RESONANCE NEUROGRAPHY OF SUPRASCAPULAR NEUROPATHY	Yu Jin Im, MD	I & II
158	DELAYED DIAGNOSIS AMONGST GENERALIZED MYASTHENIA GRAVIS PATIENTS: RESULTS FROM A EUROPEAN REAL-WORLD STUDY	Andras Borsi, MSc	I & III
159	CHANGING PRIORITIES AMONG PHYSICIAN REPORTED REASONS FOR CHOICE OF PHARMACOLOGICAL GENERALIZED MYASTHENIA GRAVIS TREATMENTS ACROSS 5 EUROPEAN COUNTRIES	Andras Borsi, MSc	I & III
160	SPINAL ACCESSORY NEUROPATHY FROM DELAYED RADIATION INJURY AND SECONDARY BRACHIAL PLEXOPATHY FROM SHOULDER DROOP	Christina Chrisman, MD	I & II
161	GAMMAGARD LIQUID FOR THE TREATMENT OF RELAPSE IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY	Mamatha Pasnoor, MD	I & III
162	MECHANICALLY INDUCED SOMATOSENSORY EVOKED POTENTIALS: GENUINE ELECTROPHYSIOLOGICAL RESPONSES OR MOVEMENT ARTIFACTS?	Rachel Pérez-Lalana, MD	I & II
163	REAL-WORLD EXPERIENCE WITH ECUZUMAB IN PATIENTS WITH MYASTHENIA GRAVIS IN JAPAN: ANALYSIS OF 2-YEAR POST-MARKETING SURVEILLANCE DATA	Mitsuru Watanabe, MD	I & III
164	ROLE OF TGF-1B GENE POLYMORPHISMS IN THE PATHOGENESIS OF CARPAL TUNNEL SYNDROME IN EGYPTIAN PATIENTS	Maha Ibrahim, MD	I & II

165	CLINICAL PROFILE OF MOTOR NEURON DISEASE IN A CENTRAL AMERICAN POPULATION	Sara Loanny Flores Lazo, MD	I & III
166	ULTRASONOGRAPHIC DIAGNOSIS IN ACUTE SEGMENTAL HERPES ZOSTER PARESIS	Sang Beom Kim, MD	I & II
167	DIAGNOSTIC UTILITY OF NERVE ULTRASONOGRAPHY ON ULNAR NEUROPATHY AT ELBOW WITH NORMAL ELECTRODIAGNOSTIC FINDINGS	Sang Beom Kim, MD	I & II
168	UNILATERAL AND BILATERAL CARPAL TUNNEL SYNDROME	Sasha Zivkovic, MD, PhD	I & III
169	PATIENT EXPERIENCE WITH ACUTE HEPATIC PORPHYRIA BEFORE AND AFTER LONG-TERM GIVOSIRAN TREATMENT: A QUALITATIVE INTERVIEW STUDY	Hetanshi Naik, PhD, MS	I & II
170	HIRAYAMA DISEASE: A ELECTROPHYSIO-RADIOLOGICAL DOCUMENTARY	Mrinal Acharya, MBBS, MD, DM	I & III
171	CAMPTOCORMIA DUE TO ISOLATED THORACOLUMBAR PARASPINAL INCLUSION BODY MYOSITIS	Cynthia De la Rosa Zapata, MD	I & III
172	AUTOIMMUNE NODONOPATHY WITH CONCURRENT MEMBRANOUS GLOMERULOPATHY DUE TO ANTI-CONTACTIN 1 AND ANTI-CASPR1 ANTIBODIES	Cynthia De la Rosa Zapata, MD	I & III
173	A CASE OF ANTERIOR DURAL TEAR MIMICKING AMYOTROPHIC LATERAL SCLEROSIS	Yuyao Sun, MD	I & II
174	SWITCHING TREATMENT FROM ALGLUCOSIDASE ALFA TO CIPAGLUCOSIDASE ALFA/MIGLUSTAT POSITIVELY AFFECTS MOTOR FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH LATE-ONSET POMPE DISEASE	Hani Kushlaf, MD	I & III
175	NIPOCALIMAB DOSE SELECTION FOR A PHASE 3 STUDY IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS	Jocelyn Leu, PhD	I & II
176	HANDHELD DYNAMOMETRY CORRELATES SIGNIFICANTLY WITH GLOBAL MANUAL MUSCLE STRENGTH IN PERIPHERAL NEUROPATHY PATIENTS	Benn Smith, MD	I & III
177	INTEGRATED ANALYSES OF DATA FROM CLINICAL TRIALS OF DELANDISTROGENE MOXEPARVOVEC IN DUCHENNE MUSCULAR DYSTROPHY	Crystal Proud, MD	I & II
178	APHERESIS AND HYPOKALEMIA IN A MYASTHENIA GRAVIS PATIENT: A CASE REPORT	Ayyemen Amaar, BS	I & III
178	ONE-YEAR DATA FROM ENDEAVOR, A PHASE 1B TRIAL OF DELANDISTROGENE MOXEPARVOVEC IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY	Crystal Proud, MD	I & II
179	CHARACTERIZATION OF MYASTHENIA GRAVIS PATIENT POPULATION AND MANAGEMENT PREFERENCES IN COLORADO	Thomas Ragole, MD	I & III
180	RAVULIZUMAB IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS: A SUB-ANALYSIS OF THE PHASE 3 CHAMPION MYASTHENIA GRAVIS STUDY ACCORDING TO CHRONIC INTRAVENOUS IMMUNOGLOBULIN USE AT STUDY ENTRY	Vera Bril, MD	I & II
181	FORMAL BALANCE ASSESSMENT IN PATIENTS WITH DIABETES AS STANDARD OF PRACTICE	James Nussbaum, PT, PhD, SCS, EMT	I & III
182	NOMOGRAM FOR PREDICTION OF PREGNANCY-RELATED CLINICAL WORSENING IN MYASTHENIA GRAVIS PATIENTS	Manqiqige Su, MD	I & II
183	IMPACT OF BASELINE POLYNEUROPATHY SEVERITY ON VUTRISIRAN TREATMENT RESPONSE IN THE PHASE 3 HELIOS-A STUDY	Emre Aldinc, MD	I & III
184	NEUROFILAMENT LIGHT CHAIN LEVELS SIGNIFICANTLY DECREASE IN RESPONSE TO TREATMENT WITH PATISIRAN OR VUTRISIRAN IN HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY	Emre Aldinc, MD	I & III
185	ROLE OF VIDEO-ELECTROENCEPHALOGRAPH IN TILT TABLE TESTING TO DISTINGUISH DIFFERENT DEGREES OF CEREBRAL HYPOPERFUSION DURING SYNCOPÉ	Ali Arvantaj, CAP, CNCT	I & II
186	THYMOMA-ASSOCIATED MYASTHENIC CRISIS: A MULTICENTER RETROSPECTIVE COHORT STUDY	Xiao Huan, MD	I & III
187	BETHLEHEM MYOPATHY CLINICAL VIEW WITH ULTRASONOGRAPHY AND ELECTRODIAGNOSIS: A CASE REPORT	Wilmer Santiago Herrera Malpica, MD	I & II
188	EFFECT OF SARS-COV-2 PANDEMIC ON OUTCOMES AND ASSOCIATED RISK FACTORS OF GUILLAIN-BARRE SYNDROME PATIENTS	Sarah Shoeb, BS	I & III
189	EFFECTS OF SARS-COV-2 PANDEMIC ON HOSPITALIZATIONS AND ASSOCIATED RISK FACTORS FOR MYASTHENIA GRAVIS EXACERBATION	Sarah Shoeb, BS	I & III
190	IDENTIFICATION OF PERINATAL FACTORS RELATED TO ELEVATED CREATINE KINASE IN NEWBORNS	Elisa Falk, MD, PhD	I & II
191	NOVEL BAG3 VARIANT IDENTIFIED IN A CASE OF ADULT-ONSET MYOFIBRILLAR MYOPATHY	Tram Nguyen, MD	I & III
192	THE MATILDA EFFECT: ARE WOMEN UNDERRECOGNIZED FOR NATIONAL AWARDS IN NEUROMUSCULAR AND ELECTRODIAGNOSTIC MEDICINE?	E. Ali Bateman, MD	I & II
193	COMPARISON OF TOLERABILITY AND SAFETY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% AND 20% THERAPIES AFTER SINGLE SUBCUTANEOUS ADMINISTRATION IN HEALTHY ADULTS	Zhaoyang Li, PhD	I & III
194	COMPARISON OF THE SINGLE-DOSE PHARMACOKINETICS OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% AND 20% IN HEALTHY ADULTS	Zhaoyang Li, PhD	I & III
195	REFERENCE VALUES OF ELECTROMYOGRAPHY STUDIES OF THE MASSETER AND TEMPORAL MUSCLES	Andersson Rozo, MD	I & II
196	A CASE SERIES: COVID-ASSOCIATED CHANGES IN PERIPHERAL MYELIN PROTEIN 22 NEUROPATHIES	Karim Mohamed, MD	I & III
197	NEGATIVE NERVE BIOPSY IS ONLY AS ACCURATE AS LOCALIZATION: CLINICAL, ELECTRODIAGNOSTIC, AND MRI FINDINGS IN THE DIAGNOSIS OF SCIATIC NEUROPATHY DUE TO CUTANEOUS GRANULOMATOUS MYCOSIS FUNGOIDES	Julie Crocker, MD	I & II
198	IDENTIFICATION OF MYASTHENIA GRAVIS EXACERBATIONS, CRISES, AND SYMPTOM BURDEN USING RULES-BASED NATURAL LANGUAGE PROCESSING APPLIED TO NEUROLOGIST CLINICAL NOTES	Jacqueline Pesa, PhD	I & II
199	IDENTIFICATION OF GENERALIZED MYASTHENIA GRAVIS AND ANTIBODY STATUS USING RULES-BASED NATURAL LANGUAGE PROCESSING APPLIED TO NEUROLOGIST CLINICAL NOTES	Jacqueline Pesa, PhD	I & II
200	REAL-WORLD CHARACTERIZATION OF CHALLENGES RELATED TO THE IDENTIFICATION AND MANAGEMENT OF MYASTHENIA GRAVIS CRISIS	Jacqueline Pesa, PhD	I & II
201	PERIPHERAL NERVOUS SYSTEM MANIFESTATIONS OF SJÖGREN SYNDROME	Kate Arner, BS	I & III
202	COMORBIDITIES IN PATIENTS WITH MYASTHENIA GRAVIS IN THE USA: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS	Ali Habib, MD	I & III

203	REPEATED CYCLES OF ROZANOLIXIZUMAB TREATMENT IN PATIENTS WITH MUSCLE-SPECIFIC KINASE AUTOANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS	Ali A. Habib, MD	I & III
204	SUBCUTANEOUS ROZANOLIXIZUMAB IN PEDIATRIC PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CLINICAL STUDY DESIGN	John Brandsema, MD	I & II
205	SEVERE PREDOMINANTLY MOTOR AXONAL POLYNEUROPATHY AND MYELOPATHY SECONDARY TO NITROUS OXIDE TOXICITY	Tseun Han James Kong, MB, BCh, BAO	I & III
206	EFFECT OF RNA INTERFERENCE ON CARDIOMYOPATHY AND POLYNEUROPATHY OUTCOMES IN PATIENTS WITH V122I VARIANT HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR OR ATTRV) AMYLOIDOSIS	Steven Roblin, PhD	I & II
207	POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF MYASTHENIA GRAVIS AND OTHER ANTIBODY-RELATED DISEASES	Stacey Dillon, PhD	I & III
208	HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY: A CASE REPORT	Bao Nguyen, MD	I & II
209	USING REAL-WORLD EVIDENCE TO UNDERSTAND THE DIAGNOSTIC JOURNEY OF PEOPLE LIVING WITH MYASTHENIA GRAVIS AND ITS IMPACT ON MENTAL HEALTH	Maurice Flurie, PhD	I & III
210	REGIONAL DISPARITIES IN TREATMENT OUTCOMES AMONG PATIENTS WITH GUILLAIN-BARRE SYNDROME	Nabeel Ahmed, BS	I & II
211	RACIAL DISPARITIES IN TREATMENT OUTCOMES AMONG PATIENTS WITH CEREBRAL PALSY	Nabeel Ahmed, BS	I & II
212	NERVE CONDUCTION STUDIES IN PATIENTS WITH FAMILIAL DYSAUTONOMIA	Joel Gutiérrez, MD, PhD	I & III
213	NERVE CONDUCTION STUDIES IN ANGELMAN SYNDROME	Suemin Yoon, MD	I & II
214	PAIN-RELATED EVOKED POTENTIALS: NORMATIVE DATA	Otto Hernandez Fustes, MD, MSc, PhD	I & II
215	ANALYSIS OF INDICATIONS FOR ELECTRONEUROMYOGRAPHIC STUDIES	Otto Hernandez Fustes, MD, MSc, PhD	I & II
216	BICKERSTAFF BRAINSTEM ENCEPHALITIS IN A YOUNG PATIENT: A CASE REPORT IN BOGOTA, COLOMBIA	Andrea Bonfante, MD	I & III
217	DESIGN OF A PHASE 2 CLINICAL PROGRAM FOR THE DEVELOPMENT OF PGN-EDO51 IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY	Jane Larkindale, PhD	I & II
218	PERIPHERAL NERVE INVOLVEMENT IN NEURONAL INTRANUCLEAR INCLUSION DISEASE: PROSPECTIVE CLINICAL AND NEUROPHYSIOLOGICAL STUDIES	Hongfei Tai, PhD	I & III
219	CELLULAR AND IN VIVO PRECLINICAL PHARMACODYNAMICS AND PHARMACOLOGY OF NIPOCALIMAB, A HIGH-AFFINITY, FULLY HUMAN ANTI FCRN BLOCKING THERAPEUTIC ANTIBODY	Leona Ling, PhD	I & II
220	OVERVIEW OF THE SAFETY PROFILE FROM EFGARTIGIMOD CLINICAL TRIALS IN PARTICIPANTS WITH DIVERSE IMMUNOGLOBULIN G-MEDIATED AUTOIMMUNE DISEASES	Kelly Gwathmey, MD	I & III
221	EARLY DIAGNOSTIC AND PROGNOSTIC VALUE OF REPETITIVE NERVE STIMULATION IN AMYOTROPHIC LATERAL SCLEROSIS	Yan Wang, MD	I & II
222	LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC+ STUDY	Yuebing Li, MD, PhD	I & III
223	THE GENERALIZED MYASTHENIA GRAVIS DIAGNOSTIC JOURNEY AND TREATMENT INITIATION: EUROPEAN AND US REAL-WORLD PERSPECTIVES FROM PHYSICIAN AND PATIENT SURVEYS	Kristina Patterson, MD, PhD	I & II
224	NON-NEUROMUSCULAR PATHOLOGIES IN PATIENTS PRIMARILY REFERRED FOR NEUROMUSCULAR ULTRASOUND: REPORT OF TWO CASES	Eman Tawfik, MD	I & III
225	A PHASE 2/3 PLACEBO-CONTROLLED, PARALLEL GROUP, RANDOMIZED WITHDRAWAL STUDY EVALUATING EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ARISE STUDY	Janice Wong, MD	I & II
226	SENSITIVITY OF ULTRASOUND OF PARASPINAL MUSCLES AND CORRELATION WITH MRI IN RADICULOPATHY	William Buxton, MD	I & III
227	QUANTITATIVE SONOGRAPHIC ASSESSMENT OF MUSCLE THICKNESS IN CARPAL TUNNEL SYNDROME	Alon Abraham, MD	I & II
228	QUANTITATIVE SONOGRAPHIC ASSESSMENT OF MUSCLE THICKNESS PREDICTS SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS	Alon Abraham, MD	I & II
229	COMBINED RITUXIMAB AND EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS	Arjun Seth, MD	I & II
230	100TH ANNIVERSARY OF THE CUTANEOUS SILENT PERIOD TEST: CURRENT RELEVANCE IN CLINICAL NEUROPHYSIOLOGY	Otto Hernandez Fustes, MD, MSc, PhD	I & III
231	"AXONAL" LANDRY-GUILLAIN-BARRE-STROHL SYNDROME IN THE LATIN AMERICAN BOOK OF 1976	Otto Hernandez Fustes, MD, MSc, PhD	I & III
232	LATE-ONSET P.VAL142ILE TRANSTHYRETIN AMYLOIDOSIS MIXED PHENOTYPE IN AN ELDERLY PERSON IN A NON-ENDEMIC AREA: A CASE REPORT IN COLOMBIA	Daniel Manrique Hernandez, MD	I & II
233	EFGARTIGIMOD TREATMENT OF GENERALIZED MYASTHENIA GRAVIS: A REAL-WORLD SINGLE-CENTER EXPERIENCE	Long Davalos Loo, MD	I & II
234	THE SPECTRUM OF CONDUCTION SLOWING IN AMYOTROPHIC LATERAL SCLEROSIS	Kazim Jaffry, BA	I & III
235	THE PROFILE OF CONDUCTION SLOWING IN DIABETIC DISTAL SYMMETRIC POLYNEUROPATHY	Kazim Jaffry, BA	I & III
236	A LONG WINDY ROAD TO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	Kristin Brown, MD	I & II
237	CHANGE IN CONCOMITANT THERAPIES FOR GENERALIZED MYASTHENIA GRAVIS IN PATIENTS RECEIVING ECULIZUMAB: A RETROSPECTIVE ANALYSIS OF REGISTRY DATA	Pushpa Narayanaswami, MD	I & III
238	CSB-9 UPREGULATION IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS	Syed Ahmed, DO	I & II
239	FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY: INTERIM RESULTS FROM A LONG-TERM SAFETY AND TOLERABILITY STUDY	Vera Bril, MD	I & III
240	A CASE OF TREATMENT WITH EFGARTIGIMOD IN A PATIENT WITH GENERALIZED MYASTHENIA GRAVIS AND LRP4 ANTIBODIES	Eduardo De Sousa, MD	I & II
241	CORTICOSTEROID MANAGEMENT IN NEUROMUSCULAR DISEASE: A CANADIAN SURVEY	Lora Stepanian, BSc	I & II
242	REAL-WORLD INSIGHTS INTO DIFFERING CLINICAL PRESENTATION OF MYASTHENIA GRAVIS PATIENTS ON PHARMACOLOGICAL TREATMENT IN THE USA AND FIVE EUROPEAN COUNTRIES	Jacqueline Pesa, PhD	I & III
243	CHARACTERISTICS OF PROGRESSIVE MYASTHENIA GRAVIS PATIENTS IN REAL WORLD PRACTICE IN THE USA AND FIVE EUROPEAN COUNTRIES	Jacqueline Pesa, PhD	I & III
244	HEALTHCARE UTILIZATION AND COSTS OF ADULTS WITH MYASTHENIA GRAVIS AND COMMON COMORBIDITY OR DISEASE ACTIVITY PROFILES	Jacqueline Pesa, PhD	I & III

245	GUILLAIN-BARRE LIKE SYNDROME WITH PLEOCYTOSIS FOLLOWING NELARABINE TREATMENT	Midori Eckenstein, MD	I & II
246	TOLERANCE OF THE NOVEL DRUG RELYVRIO IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS	Lindsay Malatesta, MD	I & II
247	RAPIDLY PROGRESSIVE AMYOTROPHIC LATERAL SCLEROSIS FOLLOWING IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY	Lindsay Malatesta, MD	I & II
248	IDIOPATHIC INFLAMMATORY MYOPATHIES AND MALIGNANCY SCREENING: A SURVEY OF THE CURRENT PRACTICES AMONGST CANADIAN NEUROLOGISTS AND RHEUMATOLOGISTS	Maria Jekielek, MD	I & III
249	UTILITY OF THE COMBINATION OF MEDIAN NERVE SOMATOSENSORY EVOKED POTENTIAL AND AUDITORY BRAINSTEM RESPONSE IN THE EARLY DIAGNOSIS OF BICKERSTAFF BRAINSTEM ENCEPHALITIS	Takamichi Kanbayashi, MD, PhD	I & II
250	A CASE OF ANTI-MI2 DERMATOMYOSITIS AFTER COVID VACCINATION	Leila Darki, MD	I & III
251	PATIENTS IN THE POMPE REGISTRY WHO SWITCHED FROM ALGLUCOSIDASE ALFA TO AVALGLUCOSIDASE ALFA: REAL-WORLD EXPERIENCE	Mazen Dimachkie, MD	I & II
252	A RARE CASE OF A PATIENT WITH PURE AUTONOMIC FAILURE AND C9ORF72+ AMYTROPHIC LATERAL SCLEROSIS: CASE REPORT	Hebatallah Rashed, MD, PhD	I & II
253	INVESTIGATING OUTCOMES OF TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A NEW YORK STATE PLANNING AND RESEARCH COOPERATION (SPARCS) STUDY	Kazim Jaffry, BA	I & III
254	DOES ELEVATED CREATINE KINASE INCREASE THE RISK OF DEVELOPING POST-ACUTE SEQUELAE OF COVID-19 IN ENCEPHALOPATHIC COVID-19 PATIENTS?	Kazim Jaffry, BA	I & III
255	TYPE 2 DIABETES EFFECT ON AMYOTROPHIC LATERAL SCLEROSIS ONSET: A NEW YORK STATE PLANNING AND RESEARCH COOPERATION STUDY	Kazim Jaffry, BA	I & III
256	RETROSPECTIVE STUDY OF SELECT ADVERSE EVENTS OF SPECIAL INTEREST ASSOCIATED WITH CORTICOSTEROID USE IN MYASTHENIA GRAVIS	Kristin Heerlein, MD, PhD, MBA	I & II
257	DESIGN OF A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (SPIREA)	Kristin Heerlein, MD, PhD, MBA	I & II
258	WEAK GLUTEUS MAXIMUS AND WEAK ILIOPSOAS WITH NORMAL GLUTEUS MAXIMUS: NEW SIGNS TO DIAGNOSE FUNCTIONAL WEAKNESS OF THE LOWER LIMBS	Masahiro Sonoo, MD, PhD	I & III
259	EFFECT OF ZILUCOPLAN ON DISEASE FLUCTUATION IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE PHASE 3 RAISE STUDY	Angela Genge, MD	I & II
260	TRAUMATIC SCIATIC NEUROMA DEMONSTRATING FASCICULAR ORGANIZATION OF PROXIMAL SCIATIC NERVE	James Dorman, MD	I & III
261	SPINAL EPIDURAL LIPOMATOSIS IN THE SETTING OF CHRONIC, LOW-DOSE STEROIDS - IMPORTANCE OF EARLY UTILIZATION OF STEROID-SPARING AGENTS	Nora Ko, MD	I & II
262	IMPROVEMENT IN MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING SUBDOMAIN SCORES IN PATIENTS TREATED WITH ECUZUMAB: RESULTS FROM A GENERALIZED MYASTHENIA GRAVIS REGISTRY STUDY	Vern Juel, MD	I & III
263	NEUROMUSCULAR ULTRASOUND AND ELECTRIC IMPEDANCE MYOGRAPHY IN CHARCOT-MARIE-TOOTH DISEASE: A PROSPECTIVE PILOT STUDY	Yohei Harada, MD	I & II
264	A CASE SERIES OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS TREATED WITH THE COMPLEMENT COMPONENT C5 INHIBITORS ECUZUMAB AND RAVULIZUMAB	Christopher Scheiner, MD, PhD	I & II
265	MATCHING-ADJUSTED INDIRECT COMPARISON OF RAVULIZUMAB/EFGARTIGIMOD IN GENERALISED MYASTHENIA GRAVIS: TIMEPOINT CHALLENGES	Christopher Scheiner, MD, PhD	I & II
266	COMPARISON OF THE RANGE OF SENSORY POTENTIALS PARAMETER VALUES BETWEEN PARTICIPANTS WITH AND WITHOUT DIABETIC NEUROPATHY BASED ON NEUROPATHY SCALE MEASUREMENTS	Ahmad Abuzinadah, MD	I & II
267	PHANTOM RADICULOPATHY: AN ELECTRODIAGNOSTIC CHALLENGE	Anelys Torres Rivera, MD	I & III
268	RESPONSE RATES WITH ZILUCOPLAN AMONG PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN AN INTERIM ANALYSIS OF RAISE-XT, A PHASE 3 OPEN-LABEL EXTENSION STUDY	Tuan Vu, MD	I & II
269	LONG-TERM SAFETY OF REPEATED CYCLES OF ROZANOLIXIZUMAB TREATMENT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS	Tuan Vu, MD	I & II
270	DOSE SELECTION AND CLINICAL DEVELOPMENT OF EFGARTIGIMOD PH20 SUBCUTANEOUS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS	Tuan Vu, MD	I & II
271	ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE MYOPATHY CAN MIMIC TYPE 2 MYOTONIC DYSTROPHY	William Baek, MD	I & III
272	EVALUATING THE SPECIFICITY OF THE WARM WATER SUBMERSION TEST FOR ERYTHROMELALGIA	J. Douglas Miles, MD	I & II
273	POSITIVE RESULTS FROM A FIRST IN-HUMAN STUDY SUPPORTING CONTINUED DEVELOPMENT OF PGN-EDOS1 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY	Michelle Mellion, MD	I & III
274	DESIGN OF A PHASE 1, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE-ASCENDING DOSES OF PGN-EDODM1 IN MYOTONIC DYSTROPHY TYPE 1	Michelle Mellion, MD	I & III
275	CLINICAL AND REAL-WORLD PHARMACOVIGILANCE DATA OF MENINGOCOCCAL INFECTIONS IN ECUZUMAB- OR RAVULIZUMAB-TREATED PATIENTS	Shirali Pandya, PhD	I & II
276	SEVERITY OF AUTONOMIC SYMPTOMS AND BLOOD PRESSURE RECOVERY PATTERNS DURING THE HEAD-UP TILT TEST IN PATIENTS WITH ORTHOSTATIC HYPOTENSION	Jungmin So, MMSc	I & III
277	CLINICALLY MEANINGFUL REDUCTION IN MYASTHENIA GRAVIS ACTIVITY OF DAILY LIVING SCORES IN 6 PATIENTS OVER 46 EFGARTIGIMOD INFUSION SESSIONS	George Small, MD	I & II
278	PATIENT-REPORTED OUTCOMES WITH HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% MAINTENANCE THERAPY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY	Colin Anderson-Smits, MPH	I & III
279	A COMPARATIVE REAL-WORLD STUDY EVALUATING THE SAFETY OF GAMMAGARD LIQUID AND OTHER INTRAVENOUS IMMUNOGLOBULIN THERAPIES FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY	Colin Anderson-Smits, MPH	I & II
280	SURVIVAL IN ETEPLIRSEN-TREATED VS DUCHENNE MUSCULAR DYSTROPHY NATURAL HISTORY PATIENTS: AN INDIRECT TREATMENT COMPARISON USING REAL-WORLD DATA	Joel Iff, PharmD, PhD	I & III



281	HETEROGENEITY FOR DIAGNOSING ULNAR NEUROPATHY AT THE ELBOW: A RETROSPECTIVE STUDY	Erika Coury, BS, R.NCS.T.	I & II
282	INTERIM ANALYSIS OF EVOLVE: A LONG-TERM OBSERVATIONAL STUDY EVALUATING ETEPLIRSEN, GOLODIRSEN, OR CASIMERSEN IN ROUTINE CLINICAL PRACTICE	Ihor Sehinovych, PharmD	I & III
283	INTERIM ANALYSIS OF EVOLVE: EVALUATING ETEPLIRSEN, GOLODIRSEN, OR CASIMERSEN TREATMENT IN PATIENTS <7 YEARS OLD IN ROUTINE CLINICAL PRACTICE	Ihor Sehinovych, PharmD	I & III
285	EFFECT OF ZILUCOPLAN ON FATIGUE IN GENERALIZED MYASTHENIA GRAVIS IN THE PHASE 3 RAISE AND RAISE-XT STUDIES	Michael D. Weiss, MD	I & III
287	ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY IN THE UNITED STATES: RETROSPECTIVE CLAIMS DATA ANALYSIS	Paola Mina-Osorio, MD, PhD	I & III
288	INCIDENCE AND PREVALENCE OF MYASTHENIA GRAVIS: ANALYSIS OF A US COMMERCIAL INSURANCE CLAIMS DATABASE	Paola Mina-Osorio, MD, PhD	I & III
289	SUBSYNOVIAL CONNECTIVE TISSUE THICKNESS IS CORRELATED WITH DISEASE STATUS AND SEVERITY IN CARPAL TUNNEL SYNDROME	Elise Robben, MD	I & III
290	EFFECT OF RAVULIZUMAB ON MYASTHENIA GRAVIS—ACTIVITIES OF DAILY LIVING ITEM SCORES IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS: POST HOC ANALYSIS OF DATA FROM THE PHASE 3 CHAMPION MG STUDY	Tahseen Mozaffar, MD	I & III
291	LONG-TERM EFFICACY AND SAFETY OF CIPAGLUCOSIDASE ALFA/MIGLUSTAT IN AMBULATORY PATIENTS WITH POMPE DISEASE: A PHASE III OPEN-LABEL EXTENSION STUDY (ATB200-07)	Tahseen Mozaffar, MD	I & III
292	THERAPEUTIC ELECTRICAL STIMULATION ACCELERATES DIAPHRAGM MUSCLE REINNERVATION IN A RAT MODEL OF SPINAL ACCESSORY TO PHRENIC NERVE TRANSFER REPAIR	Hongkai Wang, MD	I & II
293	PREVALENCE OF TRANSTHYRETIN GENE VARIANTS IN THE ROCKY MOUNTAIN WEST REGION	Dianna Quan, MD	I & III
294	FEASIBILITY AND ACCEPTABILITY OF TELEMEDICINE IN NEUROMUSCULAR CLINIC DURING COVID-19 PANDEMIC	Mehdi Ghasemi, MD, MPH	I & II

## 2022-2023 Board of Directors

---

AANEM's volunteer board of directors is responsible for the association's strategic planning, policy creation, financial oversight, and executive director supervision.

### President

Robert Irwin, MD

### President-Elect

Dianna Quan, MD

### Directors

Samuel Bierner, MD

Michael Cartwright, MD

Laura Corrigan, MD

Pushpa Narayanaswami, MD

John Norbury, MD

Benjamin Warfel, MD

### Historian

Anthony Chiodo, MD, MBA

### Secretary-Treasurer

Faye Tan, MD

### Past President

Holli Horak, MD

### Young Leadership Liaisons

James Eubanks, MD

Michael Skolka, MD

## AANEM Staff

---

AANEM thanks the following staff members for their support, time, and talents in planning and hosting the 2023 annual meeting and all they do throughout the year.

Shirlyn A. Adkins, JD  
Executive Director

Karen Kilpatrick  
Meetings & Foundation  
Coordinator

Rachel Schunder  
Marketing Coordinator

Rachel Volbrecht, JD  
Manager of Government  
Affairs

Mary Kay Costello  
Assoc. Executive/HR  
Support

Whitney Lutteke  
Communications & Graphic  
Designer

Jay Schweinfus  
Marketing & Membership  
Director

Anna Vredenburg  
Education & Professional  
Standards Manager

Sandra Furr  
Senior Education &  
Professional Standards  
Coordinator

Cristi Lyke  
Membership Services  
Coordinator

Danielle Sidenstricker  
Corporate Manager

Jennifer Walsh  
Senior Accountant

Allie Happel  
Marketing Manager

Brandon Ormsby  
IT Programmer/Analyst

Jacob Sokol  
IT Director

Carrie Winter, RHIA  
Senior Health Policy  
Manager

Shelly Jones, CAE, CPPM  
Meeting, Corporate &  
Foundation Director

Tracy Parks, CMP, CPPM  
Meetings Manager

Millie Suk, JD, MPP  
Health Policy & Standards  
Director

# Statements & Policies

## Meeting Objectives

The 2023 annual meeting will focus on improving patient care, medical knowledge, interpersonal communication, professionalism, and systems-based practices in the following areas: updates in NM and MSK disorders; status of inherited muscle diseases; genomics and emerging gene therapies; new technologies and treatments; autoimmune disorders; neuropathies, antibody testing, US, EDX, and biopsy skills.

After attending this activity, attendees will:

- Enhance their ability to obtain a comprehensive patient history and examination; improve their ability to develop a differential diagnosis and direct appropriate diagnostic work-ups; assess rehabilitation potential for patients with NM and MSK disease; treat patients with pain, utilize EMG to precisely assess the severity of nerve injuries, recognize the association of immunization with new onset of NM diseases and how COVID impacts patient care, and recognize how assessment techniques can improve the lives of patients. (Patient care)
- Develop technical skills necessary to perform neurologic, EDX, and rehabilitative procedures; identify and describe important EDX, biopsy, genetic, and US findings; develop awareness of treatments, therapies, and side effects; and discuss the latest literature on NMDs. (Medical knowledge, Practice-based learning)
- Improve ability to communicate with and educate patients, families, and members of the healthcare team; articulate a confident clinical approach to common questions faced as an inpatient consultant; demonstrate professionalism in clinical, research, and academic practice. (Interpersonal communication skills, Professionalism)
- Develop strategies for working in a multidisciplinary session, awareness of emerging treatments and therapies; identify and access supportive healthcare services and mechanisms that improve patient care and patient quality of life. (Systems-based practice)

## Accreditation Statement

The AANEM is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## AMA Credit Designation Statement

The AANEM designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Self-Assessment Credit

Self-assessment credits will be available for those attending the live in-person meeting. AANEM will report completion of this self-assessment activity to the American Board of Psychiatry and Neurology and American Board of Physical Medicine & Rehabilitation.

## Disclaimer Statement

AANEM will disclose to learners the relevant financial relationships for those in control of CME content prior to the educational activity or disclose that there were no relevant financial relationships. Information will be provided through print and verbal disclosures.

## AANEM Annual Meeting Refund Policy

The association dedicates a significant amount of time and expense to deliver a great annual meeting each year. While we hope everyone who registers for the annual meeting will be able to attend, we understand that circumstances may sometimes prevent this from happening. AANEM has established the following policy for those who request a refund.

Refund requests received prior to 60 days from the start of late registration will be refunded at 100%.

Refund requests received 60 days to 14 days from the start of late registration will be subject to a \$100 cancellation fee and any remaining amount will be refunded.

Refund requests received from 13 days through the start of late registration will be subject to a \$150 cancellation fee and any remaining amount will be credited toward future AANEM purchases (credit expires 2 years after the first day of the annual meeting). Registration fees will not be refunded after the start of late registration.\*

*\*Individual workshops, events or sessions that were purchased in addition to the standard registration fee may be cancelled during the meeting, as long as the attendee has not cancelled their standard meeting registration. A refund of 50% of the purchase price will be provided. The ticket must be returned to the registration desk to receive a refund.*

## AANEM CME Programming

It is the policy of the AANEM to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. This program is for scientific and educational purposes only and will not, directly or indirectly, promote the interests of any commercial interest. All CME sessions that are offered as part of the official AANEM Annual Meeting program are determined solely by the AANEM Annual Meeting planning committees and approved by the AANEM Board. Planning committees identify professional practice gaps, choose topics, and identify session

chairs for each session, and determine the educational format. Material presented at the sessions cannot contain any advertising, corporate logo, trade name, or product group message. All scientific research referred to, reported or used in support of justification of a patient care recommendation will conform to generally accepted standards of experimental design, data collection and analysis. Speakers are requested to provide a balanced view of therapeutic options, using generic names in presentations to contribute to impartiality. If content includes trade name, speakers are instructed to incorporate the trade names from several companies.

*Specific disclosure information for all speakers, planning committee members and course chairs participating in the 2023 Annual Meeting is provided in the Disclosure Index at the registration desk or online at [www.aanem.org/disclosures](http://www.aanem.org/disclosures).*

## Industry Forums

Industry Forums are commercially supported educational activities held in conjunction with the AANEM Annual Meeting. These sessions are not part of the AANEM's official annual meeting program and are planned by an outside company or party. These sessions are clearly labeled as "Industry Forums" to allow the participant to be fully aware of any bias in the presentations. Seating at sessions is limited, and food is provided by the AANEM to Industry Forum attendees on a first come, first-served basis.

## Permission to Use Image

By participating in AANEM's annual meeting or related activity ("Meeting"), all participants, attendees, exhibitors, and sponsors ("You") create an agreement between You and AANEM regarding the use and distribution of your image, including but not limited to your name, voice, written words, and likeness ("Image"). By attending the Meeting, you acknowledge and agree that still, video, audio and/or other digital recordings may be taken of you and you grant permission to AANEM (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by AANEM.

Audio or video recording by attendees at any session, or any time during the AANEM Annual Meeting, is strictly prohibited.